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Abstract: The salinosporamides are potent proteasome inhibitors among which the parent 
marine-derived natural product salinosporamide A (marizomib; NPI-0052; 1) is currently 
in clinical trials for the treatment of various cancers. Methods to generate this class of 
compounds include fermentation and natural products chemistry, precursor-directed 
biosynthesis, mutasynthesis, semi-synthesis, and total synthesis. The end products range 
from biochemical tools for probing mechanism of action to clinical trials materials; in turn, 
the considerable efforts to produce the target molecules have expanded the technologies 
used to generate them. Here, the full complement of methods is reviewed, reflecting 
remarkable contributions from scientists of various disciplines over a period of 7 years 
since the first publication of the structure of 1. 
Keywords:  salinosporamide A; marizomib; NPI-0052; proteasome inhibitor; total 
synthesis; semi-synthesis; natural products chemistry; fermentation; mutasynthesis; 
precursor-directed biosynthesis; structure-activity relationships; analogs 
 
1. Introduction 
The ubiquitin and proteasome dependent proteolytic system (UPS) is the major pathway for 
regulated protein degradation in eukaryotic cells [1,2]. Central to the UPS is the 26S proteasome, a  
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2.5 MDa multi-catalytic enzyme complex that houses a 700 kDa proteolytic 20S core particle in which 
protein substrate hydrolysis is executed. Substrates for this non-lysosomal protein degradation pathway 
include misfolded and defective proteins, as well as others that are selectively polyubiquitin-tagged and 
targeted for degradation by the UPS [1–3]. Proteasome structure, function, and the impact of 
proteasome inhibitors as biochemical tools and therapeutic agents have been extensively reviewed [1–6]. 
In addition to providing a mechanism for cellular protein quality control, the UPS facilitates essential 
processes ranging from antigen processing to signal transduction, cell cycle control, cell differentiation 
and apoptosis [1–4]. These critical functions, together with the ubiquitious nature of the proteolytic 
20S core particle, suggest a wealth of potential applications for proteasome inhibitors ranging from 
crop protection [7] and antiparasitics [8] to new therapies for inflammation [9] and autoimmune 
diseases [4], with demonstrated utility in the treatment of cancer [4,5,10–14].  
The proteasome's impact on diverse and essential cellular processes stems directly from its core 
function, i.e., the proteolysis of a wide variety of target proteins. In turn, inhibiting proteasome activity 
has important downstream consequences that can be used to advantage in tumor cells, for example, the 
stabilization of proapoptotic proteins (e.g., p53, Bax, IқB) and the reduction of some antiapoptotic 
proteins (e.g., Bcl-2, NF-қB), collectively inducing a proapoptotic state [4,5]. These and other findings 
provided strong rationale for targeting the proteasome for the treatment of cancer, an approach which 
received initial validation through Food and Drug Administration (FDA) approval of bortezomib   
[(R)-3-methyl-1-((S)-3-phenyl-2-(pyrazine-2-carboxamido)propanamido)butylboronic acid); PS-341; 
Velcade
®] for the treatment of relapsed and relapsed/refractory multiple myeloma (MM) in 2003 [10,11]. 
Since that time, structurally unique proteasome inhibitors with the potential to treat patients that had 
failed or were not candidates for treatment with bortezomib have entered clinical trials [5]. One such 
agent is the marine-derived natural product salinosporamide A (marizomib; NPI-0052; 1) (Figure 1) [15]. 
Accounts of its discovery and development have recently been reported [16,17] along with extensive 
preclinical indicators of strong clinical potential [5,12,13,16–22]. 
Figure 1. Structures of salinosporamide A (1), lactacystin (2), omuralide (3), PS-519 (4), 
salinosporamide C (6) and its hypothetical precursor (7), and salinosporamide I (12). 
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Identification and optimization of new inhibitors have benefited from knowledge of proteasome 
structure and biology; conversely, new proteasome inhibitors have contributed to the understanding of 
proteasome structure and function (for reviews, see [3,4,6]). The 26S proteasome comprises one or two 
19S regulatory caps and a cylindrical 20S core particle housing three pairs of proteolytic subunits, 5, 
2 and 1. These three subunit types have been ascribed chymotrypsin-like (CT-L), trypsin-like (T-L) 
and PGPH or caspase-like (C-L) activities based on their substrate preferences, and work in concert to 
degrade polyubiquitin-tagged proteins into small peptides. Substrate binding entails recognition of 
amino acid side chains (P1–Pn) by sequential binding pockets (S1–Sn) proximal to the enzyme active 
site, in analogy with other proteases. The S1 “specificity pocket” immediately adjacent to the active 
site largely confers the CT-L, T-L, and C-L sites with their preferential (albeit non-exclusive) binding 
to hydrophobic, positively-, and negatively-charged residues, respectively. Once bound, hydrolysis of 
the substrate peptide bond adjacent to S1 is catalyzed by the N-terminal threonine residue (Thr1), 
classifying the 20S proteasome among the N-terminal hydrolase family of enzymes. Thr1NH2 
putatively acts as the general base, catalyzing Thr1OH
 nucleophilic addition to the sessile substrate 
peptide bond to initiate bond cleavage. Based on this mechanism, it is perhaps not surprising that 
bortezomib and many other known proteasome inhibitors comprise peptides that are derivatized with 
reactive functional groups at the C-terminus, enabling formation of covalent adducts with   
Thr1 [3,4,6].
  
Despite the rational basis for peptidyl inhibitors, the structurally unique and terrestrially-derived 
microbial natural product lactacystin (2), comprising a -lactam substituted with a thioester and an 
isopropylcarbinol [23,24] (Figure 1), was found to specifically target the proteasome [25]. Lactacystin 
undergoes  in situ transformation to the corresponding -lactone known as “clasto-lactacystin--
lactone” or “omuralide” (3), which represents the active species that acylates Thr1O
in the proteasome 
active site [25–28]. The evolution of 2 and 3 as biochemical tools that played pivotal roles in 
identifying the proteasome catalytic residues and enhancing general understanding of proteasome 
biology marked the birth of the -lactone--lactam family of proteasome inhibitors. Moreover, the 
structures of 2 and 3 offered attractive synthetic targets that inspired elegant and inventive strategies 
(for reviews, see [29–32]). Although 3 has not been developed as a therapeutic agent, its affinity and 
specificity for the proteasome demonstrated that peptidyl inhibitors can be challenged by densely 
functionalized lower molecular weight ligands of the -lactone--lactam family. In fact, the close 
structural analog PS-519 (4) (Figure 1) was evaluated in Phase I clinical trials based on preclinical data 
demonstrating neuroprotective efficacy in a preclinical model of cerebral eschaemia [33]. Then, in a 
timely 2003 publication, Fenical and coworkers reported that the marine actinomycete Salinispora 
tropica produced the potent and structurally novel proteasome inhibitor salinosporamide A 
(marizomib; NPI-0052; 1; Figure (1) [15]. The fused bicyclic ring system of 1 revealed its structural 
relationship to 3 and suggested that the two molecules may share a common molecular target. This 
hypothesis was confirmed by assaying the two compounds for inhibition of purified 20S proteasome 
CT-L activity, and also established the enhanced potency of 1 (IC50 = 1.3 nM) versus 3 (IC50 = 49 nM) 
[15]. Moreover, 3 inhibited only CT-L activity while 1 inhibited all three proteolytic activities (CT-L, 
T-L, and C-L) [13,34]. In vitro cytotoxicity assays for 1 revealed IC50 values in the nM range against a 
panel of cancer cell lines [13,15,34], including MM, where proteasome inhibitors have shown clinical 
benefit [10,11]. Again, 1 (MM cell line RPMI 8226, IC50 = 8 nM) exhibited enhanced potency over 3 Mar. Drugs 2010, 8                                    
 
 
838
(RPMI 8226, IC50 = 3300 nM) [34]. The enhanced activity of 1 is rooted in its unique structure. While 
related to 3 by virtue of the shared -lactone--lactam core structure, 1 is distinguished by chloroethyl, 
methyl, and cyclohex-2-enylcarbinol substituents at the C-2, C-3 and C-4 positions, respectively, 
which give rise to specific and mechanistically important interactions within the proteasome active site 
that include recognition of the cyclohexenyl group by the S1 specificity pocket and acylation of the 
catalytic Thr1O
 by the -lactone followed by chloride displacement, rendering the ligand irreversibly 
bound (Figure 2) [35]. Recognizing the potential for the unique properties of 1 to translate into 
therapeutic benefit, the compound was licensed from the University of California, San Diego (UCSD) 
to Nereus Pharmaceuticals, San Diego, CA [16,17]. Intensive preclinical development included 
evaluation of marizomib in various solid tumor and hematological cancer models [12,13,16–22].   
A human MM xenograft model in immunodeficient mice demonstrated efficacy after twice weekly IV 
(0.15 mg/kg) or oral (0.25 mg/kg) administration. Specifically, 1 inhibited MM tumor growth in vivo 
and prolonged survival, without the reoccurrence of tumor in 57% of mice. With respect to proteasome 
inhibition, treatment with 1 resulted in sustained inhibition of the CT-L, T-L and C-L activities in 
packed whole blood, a profile that was distinct from bortezomib. Moreover, 1 induced apoptosis in 
MM cells that were resistant to conventional and bortezomib therapies, without affecting normal 
lymphocyte viability, and did not affect the viability of MM patient-derived bone marrow stromal  
cells [13]. Interestingly, the two structurally distinct proteasome inhibitors, marizomib (1) and 
bortezomib, triggered differential apoptotic signaling pathways, suggesting a rationale for evaluating 
them in combination; indeed, combinations of low doses of the two agents triggered synergistic   
anti-MM activity [12,13,18]. These findings established the basis for a clinical development program, 
and an Investigational New Drug (IND) application was filed with the FDA in 2005 [16,17]. Strong 
preclinical indicators were also observed in leukemia cells [19–21], including synergistic cytotoxicity 
with histone deacetylase inhibitors (HDACi) [20,21], which provided rationale for ongoing clinical 
trials combining 1 with the HDACi, vorinostat [36]. In addition to promising results in hematological 
cancer models, oral administration of 1 improved tumoricidal response to multidrug treatment in a 
colon cancer xenograft model [22]. These and other studies suggested that 1 may be efficacious against 
hematological and solid tumors either as a single agent, and/or in combination with biologics, 
chemotherapeutics and targeted therapeutic agents [17]. At the time of writing, marizomib is being 
evaluated in several concurrent phase 1 clinical trials in patients with multiple myeloma, lymphomas, 
leukemias and solid tumors, including those that have failed bortezomib treatment, as well as patients 
with diagnoses where other proteasome inhibitors have not demonstrated efficacy [5,12,16,17,36–38].  
Figure 2. Mechanism of 20S proteasome inactivation by 1. The -lactone of the inhibitor 
acylates Thr1O
,
 followed by displacement of chloride to form a 5-membered cyclic ether 
ring [35]. 
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The structure of 1, together with its enhanced potency and therapeutic potential, sparked intense 
interest from the synthetic organic chemistry community (for an earlier review, see [32]). While 
strategies towards its de novo total synthesis reaped some benefits from the teachings of omuralide 
(vide supra), the more reactive functional groups of 1, along with the additional stereocenter at C-6, 
added a new level of complexity that raised the bar of the synthetic challenge. This was answered with 
several enantioselective total synthetic routes [39–43] and complemented by a growing number of 
racemic strategies [44,45] and formal syntheses [46–50] (see Section 6. Total Synthesis of 1 ). 
Nevertheless,  S. tropica remains the most efficient producer of 1. In a key demonstration of the 
industrial potential of marine microbiology, clinical supplies of 1 are being manufactured through a 
robust saline fermentation process [16,17] (see Section 2.2. Fermentation Optimization of 1 to Clinical 
Trials Materials).
 In parallel, S. tropica was further exploited in several important ways: (i) structurally 
related natural products were identified [51–53] (see Section 2.1 Natural Products of S. tropica);   
(ii) modified media and precursor-directed biosynthesis gave rise to new chemical entities, altered the 
ratios of secondary metabolites, and offered insights into the biosynthetic pathways of 1 and   
analogs [52,54–58] (see Section 2.3 Products of Precursor-Directed Biosynthesis); (iii) access to large 
quantities of 1 through fermentation enhanced its utility as a precursor for semi-synthesis   
[34,52,59–61] (see Section 4. Products of Semi-Synthesis); (iv) its genome was sequenced [62]; and 
(v) knockout mutants were generated, opening the door to bioengineered products [63–66] (see 
Section 2.4 Products of Mutasynthesis). Here, we capture the full complement of methods for 
generating a generation of proteasome inhibitors in the salinosporamide family that have been 
developed by microbiologists and organic chemists working collaboratively or independently. The 
collective body of work reflects enormous progress over a period of 7 years since the first publication of 
1 by Fenical and coworkers [15].  
As a guide to the reader, we refer to Figure 1 and adopt the following nomenclature throughout this 
review. Based on crystallographic analysis of -lactone--lactam inhibitors in complex with the 20S 
proteasome [28,35,67] and the orientation of key substituents relative to those of peptidyl inhibitors, 
the C-4 substituent is referred to as the P1 residue, while the C-2 substituent is denoted P2 (despite its 
non-amino acid origins [68]). Other substituents and functional groups will be referred to by atom 
number according to Figure 1. All P1 and P2 analogs are captured in Tables 1 and 2, along with their 
published methods of production and their IC50 values for inhibition of purified 20S proteasome CT-L 
activity. Compounds that fall outside of these structural boundaries are captured in Figures 1 and 3 and 
Schemes 1–3. Finally, the synthetic routes for the total and formal synthesis of 1 are presented in 
Schemes 4–15. While the main focus of this review article is on methods of production, structure-activity 
relationship trends are briefly presented (see Section 5. Structure-Activity Relationships).
 
2. Natural and Unnatural Products of S. tropica 
In this section, we focus on salinosporamides generated from S. tropica, including those isolated 
from wild type and genetically modified strains. Mar. Drugs 2010, 8                                    
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2.1. Natural Products of S. tropica  
The genus Salinispora represents a group of taxonomically diverse actinomycetes that is widely 
distributed in ocean sediments [69,70]. The discovery of this marine taxon was part of a larger effort 
by Fenical and coworkers to explore the ocean as a source of new marine microbes that produce novel 
chemical entities with therapeutic potential. Strains representing three Salinispora species (tropica, 
arenicola, and pacifica) were isolated from samples collected in tropical and subtropical regions, and 
fermentation extracts produced from these strains gave rise to a high hit rate in anticancer and antibiotic 
screens. A detailed investigation of S. tropica ensued, which led to the discovery of 1 [15,16].  
S. tropica was first isolated from a heat-treated marine sediment sample collected in the Bahamas. 
The potent biological activity of crude extracts obtained from shake-flask culture and solid phase 
extraction led to the bioassay guided fractionation and isolation of the major secondary metabolite 
salinosporamide A (1) by Feling et al. [15]. Structure elucidation revealed its dense functionality 
(Figure 1), including the fused bicyclic -lactone--lactam core reminiscent of omuralide (3) and 5 
contiguous stereocenters (2R,3S,4R,5S,6S) that were unequivocally established by X-ray 
crystallography. Publication of initial findings on the source organism, structure and proteasome 
inhibitory profile of 1 in 2003 [15], when the proteasome was receiving considerable attention through 
positive clinical trials results with bortezomib [10,11], triggered a rigorous preclinical evaluation of 1 
that formed the basis for ongoing clinical trials (vide supra).  
Encouraged by the phylogenetic novelty of Salinispora and the exciting new chemistry exemplified 
by 1, research on S. tropica continued at UCSD. A thorough evaluation of crude extracts resulted in 
the identification of deschloro analog salinosporamide B (5) (Table 1) [51]. Although less potent than 
1 in terms of proteasome inhibition and cytotoxicity, 5 provided important mechanistic and 
biosynthetic insights: biochemical and structural biology studies of 5 in direct comparison with 1 
highlighted the importance of the chlorine leaving group of the parent natural product for inducing 
irreversible binding to the proteasome [35,61], while precursor-directed biosynthesis demonstrated 
distinct origins for the C1/C2/C12/C13 carbons of 1 versus 5 [55]. Salinosporamide C (6), a tricyclic 
cyclohexanone derivative of 1, was also isolated from the fermentation broth; while considered a 
natural product, rearrangement pathways from 1 involving the proposed -lactone precursor 7 were 
envisioned (Figure 1) [51]. Moreover, 7 was subsequently isolated as a byproduct of chemical 
transformations of 1 under oxidative conditions (Macherla, Manam and Potts, unpublished 
observation; see Section 4. Products of Semi-synthesis). In addition to salinosporamides A–C, S. 
tropica crude extracts contained several products of -lactone ring hydrolysis or decarboxylation. The 
ability to generate these compounds from 1 under conditions similar to those used during fermentation 
and extraction led to their assignment as degradants as opposed to natural products [51]. Nevertheless, 
these findings offered important insights into the reactivity of 1 (for structures and discussion, see 
Section 3. Products of Chemical Degradation).  Mar. Drugs 2010, 8                                    
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Table 1. Structures of 1 and P2 analogs, methods of production, and IC50 values for 
inhibition of CT-L activity of purified 20S proteasomes. 
O
H
N
O
OH
O
2
P2  
Str #  Compound Name(s)  P2  CT-L (IC50, nM)
a  Source/Method of Production 
1  Salinosporamide A 
NPI-0052  CH2CH2Cl
 
2.5 ± 1.2 [61] 
2.0 ± 0.3 [61]
b 
3.5 ± 0.3 [13]
c 
Natural Product [15] 
Total Synthesis [39–45] 
Formal Synthesis [46–50] 
5  Salinosporamide B 
NPI-0047  CH2CH3 
26 ± 6.7 [61] 
Natural Product [51] 
Directed Biosynthesis [55,56,Table 4]
Modified Media [54,58,Table 4] 
8  Salinosporamide D  CH3 
7.5 ± 0.6 [61] 
Natural Product [52] 
Directed Biosynthesis [Table 4] 
Modified Media[Table 4] 
9  Salinosporamide E  CH2CH2CH3 
24 ± 5 [34] 
Natural Product [52] 
Semi-synthesis [34] 
Directed Biosynthesis 
± Modified Media [Table 4] 
10  Salinosporamide F  CH2CH2Cl 330 ± 20 [34]  Natural Product [34,52] 
11  Salinosporamide G  CH3 
3200, 3300 [59]  Natural Product [52] 
16  Salinosporamide H  CH2CH3 1400 [59]  Byproduct of directed biosynthesis of 
15 [52] 
15  Bromosalinosporamide  CH2CH2Br 2.6 ± 0.4 [34]  Directed Biosynthesis [34,52,54] 
+ Modified Media [Table 4] 
42  Iodosalinosporamide  CH2CH2I 2.8 ± 0.5 [34]  Semi-synthesis [34] 
17  Fluorosalinosporamide  CH2CH2F
 
9.2 ± 10.2 [61] 
1.5 ± 0.05 [63]
b 
Semi-synthesis [61] 
Mutasynthesis [63,66] 
Directed Biosynthesis in Modified 
Media [Table 4] 
43  Azidosalinosporamide  CH2CH2N3 7.7 ± 1.5 [34]  Semi-synthesis [34] 
45  Thiocyano-
salinosporamide  CH2CH2SCN
 
3.4 ± 0.2 [59]  Semi-synthesis [59] 
41  Hydroxy- 
salinosporamide  CH2CH2OH
 
14 ± 1.5 [61]  Semi-synthesis [34,61] 
44    CH2CH3OCCH2CH3
O
 
7,3 [59]  Semi-synthesis [59] 
46  Mesylsalinosporamide  CH3 S
O
O
O
4.3 ± 0.8 [61]  Semi-synthesis [61] 
47  Tosylsalinosporamide  S O
O
O
2.5 ± 0.4 [61]  Semi-synthesis [61] 
Total synthesis [61] Mar. Drugs 2010, 8                                    
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Table 1. Cont. 
48  Dansylsalinosporamide
S
O
O
O
N
3.0 ± 0.5 [61]  Semi-synthesis [61] 
a  Purified rabbit 20S proteasomes, unless otherwise indicated. Where n ≥ 3, the mean   
IC50 value ± standard deviation is presented; where n < 3, results of individual experiment(s) are 
shown. 
b Purified yeast 20S proteasomes. 
c Purified human 20S proteasomes. 
 
The advancement of 1 into preclinical development at Nereus demanded a constant supply of pure 
compound, which further necessitated fermentation scale-up and process development (see   
Section 2.2. Fermentation Optimization of 1 to Clinical Trials Materials). Purification of 1 from larger 
scale crude extracts (8 g derived from 40 L of fermentation broth) facilitated the isolation and 
structural characterization of several less abundant congeners [52]. Most of these natural products 
represented modifications to P2 (Table 1), including salinosporamide D (8; P2 = methyl), the 
previously described salinosporamide B (5; P2 = ethyl), and salinosporamide E (9; P2 = propyl), the 
latter of which had first been identified by semi-synthesis [34]. Stereoisomers representing epimers at 
the C-2 position were also identified, including salinosporamides F (10) and G (11), the C-2 epimers of 1 
and  8, respectively [52]. Sampling and HPLC analysis of fermentation culture extracts over time 
indicated that the ratio of 1 to 10 was fairly constant throughout the fermentation cycle, suggesting that 
C-2 is not post-biosynthetically racemized. The corresponding diastereomer of salinosporamide B was 
not detected in the large scale crude extract but was identified in extracts obtained from modified 
fermentation conditions using NaBr-based media (see Section 2.3. Products of Precursor-Directed 
Biosynthesis). In addition to these P2 congeners, the large scale crude extract contained 
salinosporamide I (12), in which the methyl group at the C-3 ring junction is replaced with an ethyl 
group (Figure 1), and P1 analog salinosporamide J (13) (Table 2), reflecting dehydroxylation   
at C-5 [52].  
Table 2. Structures of 1 and P1 analogs, methods of production, and IC50 values for 
inhibition of CT-L activity of purified 20S proteasomes. 
O
H
N
O
O
Cl
P1
 
Str #  Compound Name(s)  P1  CT-L (IC50, nM)
a  Source/Method of 
Production 
1  Salinosporamide A 
NPI-0052 
5
6
OH
 
(5S,6S) 
2.5 ± 1.2 [61] 
2.0 ± 0.3 [61]
b 
3.5 ± 0.3 [13]
c 
Natural Product [15] 
Total Synthesis [39–45] 
Formal Synthesis [46–50] 
13  Salinosporamide J  52  2 [52]  Natural Product [52] 
 Mar. Drugs 2010, 8                                    
 
 
843
Table 2. Cont. 
36  C-5-epi-salinosporamide 
5
6
OH
 
(5R,6S) 
> 20000 [34]  Semi-synthesis [34,60] 
Total synthesis [41] 
35 
 
Keto-salinosporamide 
O
8200  600 [34] 
Semi-synthesis [34,60] 
Total synthesis [41] 
18  NPI-2056 
Salinosporamide X1 
OH
20  3 [34] 
27.5  3.7 [65]
b 
Semi-synthesis [34] 
Mutasynthesis [64,65] 
19  Salinosporamide X7 
OH
2.2  0.1 [65]
b  Mutasynthesis [65] 
20  Salinosporamide X2 
OH
9.3  1.6 [65]
b  Mutasynthesis [64,65] 
21  Salinosporamide X3 
OH
93.4  4.3 [65]
b  Mutasynthesis [65] 
14  Antiprotealide 
OH
 
 
31  5 [53]
d 
27  2 [53]
e 
101  15 [65]
b 
Natural Product [53] 
Total Synthesis [71,72] 
Mutasynthesis [64,65] 
Directed Biosynthesis  
[Table 4] 
22  Salinosporamide X5 
OH
245  38 [65]
b  Mutasynthesis [65] 
23  Salinosporamide X6 
OH
132  19 [65]
b  Mutasynthesis [65] 
24  Salinosporamide X4 
OH
1029  419 [65]
b  Mutasynthesis [65] 
37  NPI-2060 
O
OH
. 
6.3  0.6 [34]  Semi-synthesis [34] 
38  NPI-2061 
O
OH
91  8 [34]  Semi-synthesis [34] 
39  NPI-2064 
Cl OH
OH
8200  3000 [34]  Semi-synthesis [34] 
34  NPI-2157  O
OH
NR  Degradation [Scheme 1] 
Semi-synthesis [Scheme 2] 
40  NPI-2167 
O
OH
NR  Semi-synthesis [Scheme 2] 
NR: Not reported; 
a  Purified rabbit 20S proteasomes, unless otherwise indicated. The mean   
IC50 value ± standard deviation is presented, except for compound 36, for which the mean of 2 individual 
experiments is shown. 
b Purified yeast 20S proteasomes. 
c Purified human 20S proteasomes. 
d Natural product 
purified from S. tropica extracts. 
e Synthetic product. Mar. Drugs 2010, 8                                    
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Up to 2007, only natural products bearing a cyclohexenyl substituent at C-5 had been identified; 
specifically, congeners with an omuralide-like isopropyl group had not been reported. Nevertheless, 
the structural similarity between 1 and omuralide (3) inspired the total synthesis of ‘antiprotealide’ 
(14), a molecular hybrid in which the cyclohexenyl substituent of 1 is replaced with an isopropyl 
group, as contributed by Corey and coworkers in 2005 (Table 2) [71,72]. Then, in 2008, 14 was 
reported as product of bioengineering of S. tropica [64]. Meanwhile, 1 had advanced from preclinical 
to clinical development, and large scale production of clinical trials materials was undertaken at up to 
1000 L scale (vide infra). Purification of 1 from 72 g of crude extract obtained from a 350 L 
fermentation broth generated side fractions that were enriched in salinosporamide B (5) and a new 
congener, which spectroscopic analysis revealed to be identical to antiprotealide [53]. While access to 
large scale fermentation extracts facilitated in its identification, analysis of crude extracts from shake 
flask cultures of three wild type S. tropica strains confirmed the production of 14 in quite reasonable 
titers of ~1 to 3 mg/L. These findings firmly established antiprotealide as a natural product of S. 
tropica [53]. Antiprotealide represents one of a limited number of cases in which a natural product was 
identified subsequent to its synthesis. Notably, the synthesis of antiviral agent   
9-(-D-arabinofuranosyl)adenine (Ara-A) [73] preceded the production of the same compound by 
fermentation of Streptomyces antibioticus [74].  
The demonstration that wild type S. tropica strains produce antiprotealide, together with its close 
structural relationship to omuralide, begged the question of whether lactacystin-like analogs might also 
be natural products of S. tropica. Despite our thorough examination of S. tropica extracts, thioester 
analogs of the salinosporamides were not identified, nor have they been reported by other laboratories. 
In contrast, omuralide (3) is found in nature as its thioester precursor lactacystin (2) [23,24], while the 
structurally related cinnabaramides (P1 = cyclohexenylcarbinol; P2 = substituted or unsubstituted   
n-hexyl) are also found as either -lactones or thioesters [7,75]. However, these terrestrially-derived 
natural products do not bear halogen leaving groups at the P2 position. Semi-synthetic analogs of the 
marine-derived natural product 1 confirmed that the thioester form is prone to premature triggering of 
chloride displacement, rending the molecule significantly less active and offering no apparent 
advantage to the producing organism [52] (see Section 4. Products of Semi-Synthesis).  
2.2. Fermentation Optimization of 1 to Clinical Trials Materials  
In order to execute a successful preclinical development program, a reliable source of high purity 
drug substance (i.e., “active pharmaceutical ingredient” (API)) is required. The original fermentation 
conditions and the production strain (S. tropica CNB476) transferred from Fenical’s research group at 
Scripps Institution of Oceanography, UCSD, afforded the production of a few mg per liter of 1 in 
shake flask cultures. The original seed and production media contained numerous animal-derived 
media components and natural seawater that cannot be used to manufacture the API under current 
Good Manufacturing Practice (cGMP). Extensive fermentation development to replace the   
non-compliant media components and improve production was carried out at Nereus Pharmaceuticals. 
We successfully replaced seawater with a commercially available synthetic sea salt, Instant Ocean, for 
the production of 1. We also replaced all animal-derived nutrients with plant-derived nutrients to meet 
the FDA requirement. The yield improvement processes are summarized in Table 3 and discussed below. Mar. Drugs 2010, 8                                    
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It has been well documented that the addition of resins to the fermentations of reactive and/or 
highly potent secondary metabolites leads to increases in production of these metabolites [76–79]. The 
key to the initial success of yield improvement of 1 was the addition of solid resins to the production 
culture (Table 3; step 1). The inherent instability of the β-lactone ring of 1 in aqueous solution [80], 
such as in the submerged saline fermentation, was overcome by addition of solid resin to the 
fermentation in order to bind and capture 1. The addition of resin to the production culture led to an 
18-fold increase in yield in a preliminary study (Table 3). Further investigation of the resin 
stabilization effect on 1 using production strain NPS21184 (see below) established the conditions for 
the large-scale resin addition process [81]. 
Wild type strain often contains a heterogeneous population of cells that have different productivity. 
A simple experiment involves spreading the wild type strain on agar plates to obtain single colonies, 
comparing the productivity of the single colonies, and selecting the colony with the best productivity 
and/or characteristics for further studies. The second key yield improvement for 1 was the isolation of 
S.  tropica strain NPS21184, a single colony isolate directly derived from strain CNB476 without 
mutation and genetic manipulation (Table 3; step 4). Besides supporting higher production of 1, strain 
NPS21184 produces three-fold less of deschloro analog 5 than the parent strain CNB476. This is 
beneficial given that this interfering analog must be removed during API purification. 
Table 3. Fermentation yield improvement of 1 in shake flask and laboratory fermentor. 
Improvement
step 
Improvement parameters  Shake  flask 
(mg/L) 
Fermentor 
(mg/L) 
– Original  condition  4  – 
1  Effect of resins   70  25 
2  Length and timing of seed, production and resin addition 
cycle 
120 120 
3 Media  formulation  220  220 
4  Single colony isolation  330  330 
5  Statistical design media optimization   450  360 
 
When developing an industrial fermentation process, designing the fermentation medium is of 
critical importance. The fermentation medium affects the product yield and volumetric productivity, 
and also needs to comply with cGMP guidelines set by FDA. Media formulation studies (Table 3; 
steps 3 and 5) were successfully carried out to replace natural seawater and animal-derived media 
components with media components that are acceptable for cGMP manufacturing. Furthermore, 
additional yield improvement was achieved via media formulation studies. A greater than 100-fold 
increase in the production of 1 in shake flask culture was obtained after the above yield improvement 
processes with a production titer of 450 mg/L. 
The production of 1 by marine actinomycete strain NPS21184 was carried out via a saline 
fermentation process. Saline fermentation poses a major challenge in scale-up since published 
literature suggested that the 316-type stainless steel fermentors commonly found in manufacturing 
facilities are not resistant to the corrosive effect of the saline media [82]. Using a 316 stainless steel B. 
Braun Biostat-C fermentor (42 L total volume), we developed a process to overcome the corrosive 
effect of saline fermentation media based on this stainless steel fermentor. The foaming, aeration and Mar. Drugs 2010, 8                                    
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agitation issues associated with the scale-up production of 1 in fermentors were also addressed using 
the B. Braun Biostat-C fermentor. 
We successfully transferred the yield improvement conditions developed in shake flasks to a 
laboratory fermentor as shown in Table 3. A titer of 360 mg/L for 1  was achieved in the 42 L 
laboratory fermentor, which is lower than the maximum titer of 450 mg/L detected in shake flask. The 
discrepancy in titers is due to the foaming problem that occurred in the fermentor (but not in shake 
flask) when rich media containing high concentrations of starch and soy type products were used.  
Marizomib (1) API is currently manufactured under cGMP through a robust saline fermentation 
process by S. tropica strain NPS21184 at two different contract manufacturing organizations. The final 
fermentation process development effort standardized parameters such as temperature exposure, 
operating parameters, cleaning and passivation to overcome the corrosive effect of saline fermentation, 
and was performed in 500–1500 L industrial stainless steel fermentors. This, together with careful 
design of the timing and method for introducing the resin to the production fermentor, resulted in 
production titers of 250–300 mg/L in 500–1500 L industrial fermentors. During the peak production 
cycle, the resin-bound drug is collected, filtered, extracted with ethyl acetate and concentrated for 
downstream processing (DSP) in an environment with appropriate containment for a high biological 
potency substance. To maintain optimal stability of 1, all DSP steps are executed in non-aqueous 
solvent systems. The crude extracts from the resin undergo purification involving a highly effective 
silica gel flash chromatography step, which removes all unrelated substances as well as most 
congeners of 1, such as the deschloro analog 5. In fact, the purity of 1 increases from ~55% to ~95% 
(UV area by HPLC) after this single flash chromatography step. The resulting highly purified API 
obtained after flash chromatography may contain up to ~3% of diastereomeric impurity 10. Using an 
evaporative crystallization process that exploits subtle solubility differences between 1 and 10, this 
impurity is reduced to <1%, and 1 is isolated as a white crystallize solid. The final pharmaceutical 
grade cGMP marizomib API is obtained in >98% purity with overall ~50% recovery from the crude 
extract. Based on the potency of 1, the production titer at fermentor scale and the recovery yield are 
adequate for both clinical development and commercial production. To the best of our knowledge, this 
represents the first manufacture of clinical trial materials by saline fermentation. 
2.3. Products of Precursor-Directed Biosynthesis 
Precursor-directed biosynthesis is the addition to the fermentation medium of an analog of a part of 
the secondary metabolite which the organism is then capable of incorporating into its enzymatic 
process to yield a modified metabolite. The production of new secondary metabolites using directed 
biosynthesis is an attractive, efficient and simple-to-use method that has wide application in the field 
of industrial secondary metabolite production [83–87]. We have successfully employed this technique 
in increasing the production of minor salinosporamides and generating novel salinosporamides in   
S. tropica fermentations (Table 4).  
One of our key successes in applying this technique to generate novel salinosporamides was in 
developing the proper media to support the production of the novel analogs. In the NaCl-based 
medium, 1 is the major product of the fermentation with a titer of 277 mg/L (Table 4, condition 1). 
Several minor P2 analogs, such as 8 (P2 = methyl; 0.15 mg/L), 5 (P2 = ethyl; 4.4 mg/L) and 9  Mar. Drugs 2010, 8                                    
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(P2 = propyl; 0.11 mg/L), are coproduced in the S. tropica NPS21184 fermentation (Table 4, condition 
1). Replacing the NaCl-based medium with a NaBr-based medium produced a novel brominated 
analog (15) as the second major salinosporamide (19 mg/L) in the fermentation (Table 4, condition 2). 
The major salinosporamide produced was deschloro analog 5 (80 mg/L), while 1 was only a minor 
component (1.2 mg/L) in the fermentation (Table 4, condition 2) [54]. The increased production of 5 
was accompanied by the presence of its C-2 epimer 16 [52].  
We developed a Na2SO4-based medium with no discrete chloride ion added to this medium to 
suppress the production of 1 (Table 4, condition 3). The production of 1 was significantly reduced to 
53 mg/L while the productions of 5, 8 and 9 were increased by 64 to 127% (Table 4, condition 3). By 
feeding 1.5% NaBr to this Na2SO4-based medium, the production of bromosalinosporamide (15) was 
significantly enhanced and was the major salinosporamide produced in the fermentation (73.3 mg/L) 
(Table 4, condition 4). The production of 1 was further reduced to 18.7 mg/L in the NaBr-fed medium 
(Table 4, condition 4). The result from this feeding study confirmed that bromide ion enhanced the 
production of 5 by 3-fold with a production titer of 22.3 mg/L (Table 4, condition 4; Zhu and Lam, 
unpublished observations). 
Table 4. Production of salinosporamides (mg/L) by precursor-directed biosynthesis using 
wild-type S. tropica strain NPS21184. 
Condi-
tion 
Precursor 
1 
Chloro 
15 
Bromo 
17 
Fluoro 
14 
Antipro-
tealide 
5 
Ethyl 
8 
Methyl 
9 
Propyl 
1 [53]  None (NaCl-based medium)  277  0  0  3.0  4.4  0.15 0.11 
2 [54]  NaBr (NaBr-based medium)  1.2  19.4  0  0  80.3  0  0 
3 
None 
(Na2SO4-based medium) 
53  0  0  ND  7.3 0.34 0.18 
4 
1.5% NaBr 
(Na2SO4-based medium) 
18.7 73.3  0  0  22.3  0  0 
5 
0.025% 5′-FDA 
(Na2SO4-based medium) 
48.1 0 55.8  ND  2.9  Trace  Trace 
6 
1% Valerate 
(Na2SO4-based medium) 
45 0  0  ND 8.3  0.12  145 
7 
1% Propionate 
(NaCl-based medium) 
222 0  0  0  5.2  4.81 0 
8 [55] 
1% Butyrate 
(NaCl-based medium) 
189  0 0  ND  19.0  0 0 
9 
1% Valerate 
(NaCl-based medium) 
131 0  0  ND 5.0  0.15  121 
10 
1% Valine 
(NaCl-based medium) 
177  0 0  0 16.7  0 0 
11 
1% Leucine 
(NaCl-based medium) 
112  0 0  11 11  0.43  0.23 
12 
1% Isoleucine 
(NaCl-based medium) 
71 0  0  0  6.6  4.63  0 
ND = Not determined. Mar. Drugs 2010, 8                                    
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Incorporation of fluorine could not be achieved via the approach used to generate 
bromosalinosporamide, as NaF (1–2%) inhibits the growth of the organism [54]. Moreover, fluoride is 
not a substrate for the chlorinase enzyme that catalyzes the synthesis of the 5′-chloro-5′-
deoxyadenosine (5′-ClDA) precursor to 1 [68]. Replacing the salL  chlorinase gene by the 
Streptomyces cattleya FlA fluorinase gene in S.  tropica, Eustăquio  et al. demonstrated that the 
resulting S. tropica salL
– FlA
+ mutant strain can accept fluoride as a substrate for the production of 
fluorosalinosporamide (17) at a concentration of 4 mg/L [66]. The semi-synthesis of 17 was reported 
by Manam et al. in 2008, but the yield was low [61] (see Section 4. Products of Semi-Synthesis). The 
production of 17 by mutasynthesis (feeding 5′-fluoro-5′-deoxyadenosine (5′-FDA) to a salL
– knockout 
mutant of S. tropica; see Section 2.4. Products of Mutasynthesis) was reported by Eustăquio and 
Moore [63], however, both the volumetric productivity (1.5 mg/L) and conversion yield (5%) were 
low. Another application of the Na2SO4-based medium is the production of 17 by feeding 0.025%  
5′-FDA to the medium. We obtained a volumetric productivity of 17 at 55.8 mg/L with a conversion 
yield of 22% by precursor-directed biosynthesis in the Na2SO4-based medium (Table 4, condition 5) 
(Lam, Tsueng, Potts and Macherla, unpublished observation), significantly superior to the 
mutasynthesis method. Furthermore, 17 is a minor salinosporamide in the fermentation produced by 
the mutasynthesis approach. In contrast, 17 is the major salinosporamide in the fermentation of the 
Na2SO4-based medium produced by the precursor-directed biosynthesis approach.  
Antiprotealide (14) is a molecular hybrid comprising the core structure of 1 with the omuralide (3)-
derived isopropyl group in place of the cyclohexene ring. 14 was first characterized by Corey and 
coworkers as a synthetic analog [71,72] and then as an unnatural salinosporamide produced by a 
genetically engineered strain of S. tropica [64]. While McGlinchey et al. reported that the parent type 
strain S. tropica CNB440 did not produce 14, ~0.5 mg/L was detected in the S. tropica salX
– mutant in 
which the pathway for the biosynthesis of the cyclohexenyl moiety (L-3-cyclohex-2
′-enylalanine) of 1 
had been inactivated. Feeding 0.38 mM L-leucine to the S. tropica salX
– fermentation increased the 
production of 14 by 2-fold to ~1 mg/L and established that L-leucine is the biosynthetic precursor of 
14 [64] (see 2.4. Products of Mutasynthesis). We observed the production of 14 in three wild type 
strains of S. tropica, including the type strain CNB440 with a production titer of 1.1 mg/L, thereby 
establishing for the first time that antiprotealide (14) is indeed a natural product [53] (see 2.1. Natural 
Products of S. tropica). The best production of 14 was observed in S. tropica NPS21184, a single 
colony isolate derived directly from wild type strain CNB476 without any mutation or genetic 
modification, with the titer of 3.0 mg/L (Table 4, condition 1). We later demonstrated that feeding 1% 
L-leucine to the S. tropica NPS21184 fermentation increased the production of 14 by 3.7-fold to   
11 mg/L (Table 4, condition 11; Tsueng and Lam, unpublished observation). 
We also examined the effect of feeding 1% L-isoleucine to the S. tropica NPS21184 fermentation, 
which increased the production of 8 from 0.15 mg/L (Table 4, condition 1) to 4.63 mg/L while 
completely inhibiting the production of antiprotealide (Table 4, condition 12). The 31-fold increase in 
production of 8  in the L-isoleucine-fed culture might be due to the fact that L-isoleucine is the 
precursor of propionate [88], which in turn, is the precursor of the contiguous three-carbon unit   
C-1/C-2/C-12 of 8. The above postulation was confirmed by feeding 1% propionate to the S. tropica 
NPS21184 fermentation, which led to a similar production of 8  as in the L-isoleucine-fed culture Mar. Drugs 2010, 8                                    
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(Table 4, condition 7). We further demonstrated that [
13C] propionate was incorporated into 8 (Tsueng, 
McArthur, Potts and Lam, unpublished observations).  
Feeding 1% L-valine to the S. tropica NPS21184 fermentation increased the production of 5 from 
4.4 mg/L (Table 4, condition 1) to 16.7 mg/L while the production of antiprotealide was completely 
inhibited (Table 4, condition 10). The 3.8-fold increase in production of 5 in the L-valine-fed culture 
might be due to the fact that L-valine is the precursor of butyrate [88], which in turn, is the precursor of 
the contiguous four-carbon unit C-1/C-2/C-12/C-13 of 5 [55]. The above postulation was confirmed by 
feeding 1% butyrate to the S. tropica NPS21184 fermentation, which led to a similar 4.3-fold increase 
and production of 5 at 19 mg/L as in the L-valine-fed culture (Table 4, condition 8). The production of 
5 in the control culture and the butyrate-fed culture were significantly less than reported in our 
previous publication [55] because the NaCl-based medium used in this study contains cobalt chloride. 
We have demonstrated that cobalt and vitamin B12 inhibit the production of 5 [58]. Even though the 
absolute amounts of production of 5 in these two studies are different, the effect of butyrate in 
increasing the production of 5 is the same (4.3-fold versus 4.2-fold). In the earlier study, we also 
confirmed the incorporation of [U-
13C4]butyrate into 5; feeding sodium [U-
13C4]butyrate to S. tropica 
cultures enhanced the production of 5 by over 300% while inhibiting production of 1 by over 25%. 
NMR analysis confirmed the incorporation of butyrate as a contiguous 4-carbon unit (C-1/C-2/C-12/C-13) 
into 5 but not 1, providing the first direct evidence that the biosynthesis of 5 is distinct from 1 and that 
5 is not a precursor of 1 [55]. The precursor for the chloroethyl group of 1 was subsequently identified 
as 5′-ClDA [68]. 
The production of 9 by S. tropica NPS21184 is extremely low at 0.11 mg/L, compared to the 
production of 1 at 277 mg/L in shake flask culture (Table 4, condition 1). Feeding 1% valerate to the  
S. tropica NPS21184 fermentation in the NaCl-based medium led to a 1,100-fold increase in 
production of 9 to 121 mg/L and concomitant decrease in the production of 1 by 53% to 131 mg/L 
(Table 4, condition 9). We demonstrated the incorporation of valerate labeled with deuterium into 9 at 
the contiguous five-carbon unit C-1/C-2/C-12/C-13/C-16 and thereby established that valerate is the 
precursor of 9. Even though the production of 9 was increased by 1,100-fold and was similar to the 
production of 1 in the valerate-fed culture grown in NaCl-based medium, the isolation of 9 was a 
major challenge due to the close chromatographic elution profile of 9  and  1. We overcame this 
purification challenge by feeding 1% valerate to the S. tropica NPS21184 fermentation in the   
Na2SO4-based medium. While there was only a 20% increase in the production of 9  in the   
Na2SO4-based medium, the production of 1 decreased to 45 mg/L due to the reduction of chloride ion 
in the Na2SO4-based medium. With a significant increase in the ratio of 9 to 1, the purification of 9 
from 1 can now be achieved (Tsueng, McArthur, Potts and Lam, unpublished observations). 
The above account demonstrates that precursor-directed biosynthesis together with the use of 
proper media represents a powerful technique for increasing the production of minor salinosporamides 
and generating novel salinosporamides.  
2.4. Products of Mutasynthesis 
Mutasynthesis, or mutational biosynthesis, is a term originally defined by Nagaoka and Demain 
[89] and by Rinehart and Stroshane [90] for the concept that an exogenous moiety is needed for the Mar. Drugs 2010, 8                                    
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synthesis of a secondary metabolite by a mutant of the producing organism. The mutant which requires 
this special nutrient to produce a product peculiar to that organism has been termed an “idiotroph” 
[89]. Application of mutasynthesis in generating novel analogs of different classes of medically 
important secondary metabolites has been well documented [91–95].  
Bioinformatic analysis of the salinosporamide biosynthetic gene cluster (sal) from the genome 
sequence of S. tropica CNB440 [62] revealed a subset of genes that were subsequently exploited for 
the bioengineering of new analogs by Moore and coworkers. To eliminate production of the 
nonproteinogenic amino acid L-3-cyclohexen-2′-enylalanine precursor to the P1 substituent of 1, the 
prephenate dehydratase homologue gene salX was targeted for genetic disruption via PCR-based 
mutagenesis. Fermentation of the S. tropica salX
– disruption mutant, complemented by feeding select 
substrate amino acid precursors (proteinogenic, nonproteinogenic, and synthetic), successfully 
generated several target P1 analogs, including alicyclics 18–21 bearing cyclohexyl, cyclopentenyl, 
cyclopentyl, and cyclobutyl groups, respectively; branched aliphatic antiprotealide (14); straight chain 
aliphatics 22 and 23; and phenyl analog 24 [64,65]. Using a similar approach, Eustăquito and Moore 
targeted SalL [63]. SalL chlorinates S-adenosyl-L-methionine to produce 5′-ClDA, the C1/C2/C12/C13-
Cl precursor of 1, and does not accept fluorine as a substrate [68]. Thus, fluorosalinosporamide (17) was 
generated by feeding 5′-FDA to a salL
– knockout mutant of S. tropica that had lost the capacity to 
produce 1 [63]. Recently, Eustăquio et al. demonstrated that replacing the salL chlorinase gene in  
S. tropica with a Streptomyces cattleya FlA fluorinase gene resulted in an S. tropica salL
– FlA
+ mutant 
strain that can accept fluoride as a substrate for the production of 17 at a concentration of 4 mg/L [66]. 
Fluorosalinosporamide has also been generated in low yield semi-synthetically [61] (vide infra), but 
now most successfully by directly feeding 5′-FDA to the wild-type S. tropica strain in a Na2SO4-based 
medium, as reported herein (see 2.3. Products of Precursor-Directed Biosynthesis). 
3. Products of Chemical Degradation 
While highlighting chemical degradation in an account devoted to methods of preparing intact 
target molecules may seem unusual, knowledge of the mechanisms by which 1 is degraded led to the 
incorporation of appropriate precautionary measures and processes to circumvent or attenuate 
degradation during API manufacturing (vide supra), formulation development, and processing of blood 
samples for pharmacokinetic analysis. Moreover, the products of -lactone ring opening effectively 
anticipated the chemical mechanism of inhibition of the 20S proteasome by 1 [34,35]. 
Chemical degradants of 1 are largely formed via -lactone ring hydrolysis or decarboxylation, with 
oxidation of the cyclohexene ring occurring as a minor pathway (Scheme 1). Methanolysis of the  
-lactone to the corresponding methyl ester 25 was noted in the original account of the discovery of  
1 [15] and formally characterized by Williams et al. [51]. Unveiling of the C-3 tertiary alcohol upon 
cleavage of the -lactone ring was followed by intramolecular nucleophilic displacement of chloride to 
give 26. We subsequently reported the analogous carboxylic acids NPI-2054 (27) and NPI-2055 (28) 
as products of aqueous hydrolysis, which was highly accelerated in base but occurred very slowly in 
acid. These structures led us to propose that chloride elimination may occur subsequent to 
Thr1O
acylation at the proteasome active site (Figure 2) [34], which was later confirmed by 
crystallography of 1 in complex with the yeast 20S proteasome [35]. Detailed kinetic studies by Mar. Drugs 2010, 8                                    
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Denora et al. [80] demonstrated that -lactone ring hydrolysis occurs via standard ester hydrolysis (as 
opposed to a carbonium ion mechanism) and is moderately buffer-catalyzed, pH-independent in the 
range of 1–5, and base-dependent above pH 6.5. A kinetic deuterium isotope effect showed that the 
rate-determining step involves only a single proton transfer, suggesting that the neighboring C-5OH 
(as opposed to a second water molecule) facilitates attack of water at the -lactone ring. The 
subsequent nucleophilic displacement of chloride is also moderately buffer catalyzed. The data 
suggested that 27 exists in the carboxylate form above pH 4; at lower pH values, the (protonated) 
carboxylic acid is expected to inhibit further degradation: the rate of conversion from 27 to 28 was 
slowest in the pH range 1–3; a plateau or pH-independent region was observed at pH 4.5–6.5; and at 
pH > 7, the degradation rate increased with increasing pH [80]. While reactions in aqueous buffer 
cannot directly model the drug-enzyme complex, these findings are consistent with base (Thr1NH2) 
catalyzed nucleophilic displacement of the halide in the proteasome active site [35,67]. In fact, Thr1N is 
sufficiently basic to catalyze the unusual reaction of fluoride displacement from an sp3-carbon in the case 
of fluorosalinosporamide (17), which recently led us to propose a proteasome Thr1NH3
+ pKa > 10 [67]. 
The second dominant mechanistic pathway for the degradation of 1 involves decarboxylation 
(Scheme 1). Three products of this pathway (29, 30 and 31) were isolated from S. tropica crude 
extracts; direct conversion of 1 to these same products under pH conditions identical to those used 
during fermentation allowed them to be assigned as degradants as opposed to natural products [51]. It 
was proposed that the two diastereomers are generated with retention of configuration at C-5 (29 and 30) 
followed by dehydration to give 31. During the course of our semi-synthetic studies, we frequently 
observed the formation of these same products at elevated pH, particularly in the presence of tertiary 
amines. The diasteromeric pair 29 and 30 could be purposefully generated in the presence of 
triethylamine in dichloromethane at 40 °C; concentration at elevated temperatures gave 31 as a 
byproduct. Low levels of these same degradants were also detected during cGMP stability studies of 
the parenteral Phase 1 cosolvent formulation of 1 [0.24 mg/mL in 98% propylene glycol, 2% ethanol], 
particularly under accelerated (elevated temperature) conditions (Manam, Macherla and Potts, 
unpublished observations). Overall, we observed that the C-4 diasteromers 29 and 30 formed first, 
followed by 31, supporting the earlier suggestion that C-4/C-5 dehydration occurs as the final step in 
the degradation pathway. Degradant 32 was also detected during cosolvent formulation stability 
testing, and presumably results from further oxidative cleavage of the C-4/C-5 double bond of 31. The 
relatively high UV extinction coefficient for these conjugated compounds overestimates their presence 
in samples when not corrected for relative UV response. The unusual degradant 33 has also been 
observed under some conditions, which reflects decarboxylation with chloride displacement, giving 
rise to a spiro-cyclopropyl group (Macherla, Mitchell, McArthur and Potts, unpublished observations). 
Long-term and accelerated stability studies of 1 indicate that the API is highly stable when stored as 
a solid. The only observed degradation pathway involved exceedingly slow oxidation of the 
cyclohexene ring to the corresponding cyclohexenone 34 (Macherla, Manam and Potts, unpublished 
observation) (Scheme 1), the structure of which was confirmed by semi-synthesis (vide infra) and is 
reminiscent of the natural product salinosporamide C (6) (Figure 1) [51]. 
The above summary provides a window into the precautions required when generating and handling 
1, and serves as a preface to the following discussion on the opportunities and challenges of using 1 as 
a starting material for semi-synthesis.  Mar. Drugs 2010, 8                                    
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Scheme 1. Degradation pathways for 1: Hydrolysis, oxidation, and decarboxylation. 
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4. Products of Semi-Synthesis 
Process development for API manufacturing gave way to gram quantities of 1 to support preclinical 
studies and formulation development, and afforded an opportunity for the semi-synthesis of analogs. 
This windfall of material was tempered by challenges associated with the potential reactivity and 
instability of the functional groups of 1, including the double bond of the cyclohexene ring, the   
-lactone ring, and the chloroethyl group, as discussed above. Indeed, these same functional groups 
required careful consideration in the development of successful strategies for the total synthesis of 1 
(vide infra). Nevertheless, we set out to modify the various structural elements using a classical semi-
synthesis approach. With respect to the cyclohexenyl carbinol (P1 residue; Table 2), the C-5 secondary 
hydroxyl group proved difficult to derivative due to steric hindrance, as originally noted by Fenical 
and coworkers [15]. Oxidation to the ketone 35 [Dess-Martin periodinane; CH2Cl2] and subsequent 
reduction [NaBH4; monoglyme + 1% water; −78 °C] gave 36, the C-5 epimer of 1 in 90% 
diastereomeric excess (de), along with parent compound 1 as a byproduct [34,60]. We subsequently 
explored many commercially available reagents and reaction conditions in attempt to control the de in 
favor of 1, but without favorable outcome [60]. This led us to evaluate the potential for ketoreductase 
enzymes to execute the stereoselective reduction. After screening a library of ~100 ketoreductases, two 
enzymes (KRED-EXP-B1Y and KRED-EXP-C1A; BioCatalytics, Inc., Pasadena, CA) were identified 
that cleanly converted ketosalinosporamide 35  to  1 with complete stereoselectivity [60]. 
Foreknowledge of the utility of this reaction was strategic in the development of an endgame for our 
total synthesis of 1, which was successfully completed upon executing the reduction as the final 
transformation in the sequence [41] (see Section 6.1.3. Nereus (Ling) Enantioselective Synthesis). 
Efforts were also extended towards modification of the cyclohexene ring, the published scope of 
which encompassed reduction [10% Pd/C, H2; acetone] to give 18  [34], which was subsequently 
produced by mutasynthesis [64,65], epoxidation [mCPBA; CH2Cl2] of both faces of the cyclohexene 
ring (37 and 38) and subsequent halohydrin formation [HCl; acetonitrile] to give 39 [34]. Oxidation 
using t-BuOOH and CoAc2 produced a mixture of cyclohexenones, 40 and 34; during reversed phase Mar. Drugs 2010, 8                                    
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HPLC purification of the latter, intramolecular Michael addition of the lactam nitrogen to the 
cyclohexenone gave tetracyclic product 7 (Macherla, Manam and Potts, unpublished observations). 
We note that 7 is identical in structure to the hypothetical precursor to salinosporamide C (6) (Scheme 2) 
proposed by Williams et al. [51]. Oxidative cleavage of the cyclohexene ring double bond to create an 
acyclic substituent for further derivatization was also explored. In light of the role of P1 in recognizing 
the S1 specificity pocket of the proteasome substrate binding site, further exploration of P1 analogs is 
warranted. Efforts to generate P1 diversity using mutasynthesis are particularly encouraging [64,65] 
(see Section 2.4. Products of Mutasynthesis). In contrast, the only P1 analog generated to date by total 
synthesis is antiprotealide (14) [71,72], although this likely reflects the propensity of the synthetic 
organic chemistry community to target the parent natural product. Clearly, several key synthetic 
intermediates are excellent candidates for introducing novel P1 architecture (vide infra). With a variety 
of complementary methods now available, the authors anticipate a more extensive evaluation of P1, 
including the design and ‘synthesis’ (by any means) of subunit-specific inhibitors.  
Scheme 2. Oxidation of 1 gave a mixture of cyclohexenones 34 and 40. Decomposition of 
34 gave 7, the hypothetical precursor to salinosporamide C (6). 
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Semi-synthetic modifications to P2 (Scheme 3) were largely achieved through derivatization of two 
substrates, hydroxysalinosporamide (41) and iodosalinsoporamide (42). The parent (chlorinated) 
compound 1 was found to undergo a slow and low yielding transformation to iodosalinosporamide 
(42) [NaI; acetone; 11% in 6 days at RT]; bromosalinosporamide (15) was a superior starting material 
for this transformation [NaI; acetone; 84% in 2 days] but was not available in the same abundance as 1 
in our laboratory [34,61]. The utility of 42 as a substrate for further analoging is clearly based on the 
greater propensity of iodide to displacement compared to chloride. Treatment of 42 with Gilman’s 
reagent in dry THF at −78 °C gave the corresponding propyl analog 9 [34], which we subsequently 
identified in S. tropica crude extracts as the natural product salinosporamide E [52]. Azido [NaN3; 
DMSO], propionate [Na(C2H5CO2); DMSO] and thiocyano [NaSCN, diethylamine; acetone] Mar. Drugs 2010, 8                                    
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derivatives (43–45) were also prepared from 42 [34,59]. Despite the susceptibility of the -lactone ring 
to base-catalyzed hydrolysis, brief treatment of 42 with NaOH [5N; acetone] afforded a complex 
mixture from which the first sample of hydroxysalinosporamide (41) was isolated, albeit in low   
yield [34]. Efforts to generate fluorosalinosporamide (17) to complete the halogen series using AgF in 
THF surprisingly gave the hydroxyl analog 41 as the major product (15%), with the target fluorinated 
17 as a very minor byproduct [61]. AgF reagent has known utility in introducing fluorine in place of 
iodine or bromine [96,97], but in our hands gave rise to a hydroxy group. As 41 proved to be another 
important substrate for derivatization (vide infra), we sought to optimize its production by further 
exploring the utility of AgF reagents. This led to a 1-step method to convert the parent chlorinated 
natural product 1 directly to 41 using AgF supported on CaF2 in 35% yield (Macherla, Manam and 
Potts, unpublished observation). Hydroxyl analog 41  was subsequently used to generate analogs 
bearing non-halogen leaving groups, including mesyl, tosyl, and dansyl derivatives (46–48) [61], the 
latter of which may provide utility for fluorescence monitoring. Various carboxylate esters were also 
prepared. The P2 analog series has been evaluated for the ability to induce prolonged duration 
proteasome inhibition in vitro and firmly established the role of the leaving group at C-13 in inducing 
irreversible binding to the proteasome [61] (see 5. Structure-Activity Relationships).  
Scheme 3. Overview of the semi-synthesis of P2 analogs. 
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With no evidence for naturally occurring thioesters in place of the -lactone ring in S. tropica crude 
extracts (see Section 2.1. Natural Products of S. tropica), we endeavored to prepare them semi-
synthetically. Treatment of 1 with methyl-3-mercapto-propionate or N-acetyl-L-cysteine methyl ester 
gave the corresponding thioesters 49 and 50, which underwent slow and partial intramolecular 
nucleophilic displacement of chlorine to give cyclic ethers 51 and 52 (Figure 3). Salinosporamide B 
(5) was similarly derivatized (53). While proteasome inhibition assays suggested that the thioester may 
directly react with the proteasome, those species that retained the potential to reform the -lactone ring 
i.e., 49, 50 and 53, were more potent inhibitors of proteasome activity than cyclic ethers 51 and 52 [52] 
(see Section 5. Structure-Activity Relationships). As premature chloride elimination disables the 
molecule’s full inhibitory potential, it is no wonder that thioester analogs of the salinosporamides have 
not been found in nature. Nevertheless, if the cellular metabolism pathways identified for omuralide 
and lactacystin [27,98] are relevant to the salinosporamides, then thioesters may indeed be generated 
upon in vivo administration of 1. Preliminary studies suggest that this may be the case. 
Figure 3. Thioester derivatives of 1 and 5. 
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5. Structure-Activity Relationships 
Structure-activity relationship (SAR) trends are evaluated below with respect to inhibition of CT-L 
activity against purified 20S proteasomes. IC50 values for P1 and P2 analogs are captured in Tables 2 
and 1, respectively.  
5.1. -Lactone Derivatives 
The -lactone ring of 1 and other salinosporamides directly acylates the proteasome active site 
residue Thr1O
(Figure 2), as demonstrated by crystal structures of various analogs in complex with 
the yeast 20S proteasome [35,67]. It is therefore not surprising that modification of the -lactone ring 
has a major impact on proteasome inhibition. Indeed, degradation product 28 (Scheme 1) shows no 
CT-L inhibitory activity at the highest concentrations tested (IC50 > 20 µM) [34]; this is consistent 
with the loss of both the -lactone that acylates the proteasome and the chloroethyl trigger that induces 
sustained proteasome inhibition (vide infra). It was not possible to directly evaluate -lactone Mar. Drugs 2010, 8                                    
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hydrolysis product 27 due to rapid conversion to 28 upon attempted purification. While thioesters of the 
salinosporamides are not found in nature, they have been generated by semi-synthesis (Figure 3) [52]. 
The thioester derivative of salinosporamide B is only half as potent as its -lactone precursor   
(5: IC50 = 26 nM; 53: IC50 = 50 nM). Interestingly, when salinosporamide A (1) was similarly 
derivatized, the corresponding thioester could be isolated in both the C-3OH (seco) (e.g., 49, 50) and 
cyclic ether (e.g., 51,  52) forms. The thioester derivative in the cyclic ether form retains modest 
proteasome inhibitory activity (51: IC50 = 230 nM), indicating that the less reactive thioester can still 
bind and inhibit CT-L activity, but with ~100-fold less potency than 1 (IC50 = 2.5 nM). In the seco 
form, C-3O can either displace chloride or undergo the competing reaction of in situ  -lactone 
reformation. Since the seco form is ~25-fold more active (49: IC50 = 9.3 nM) than the corresponding 
cyclic ether 51, but only ~4-fold less potent than the -lactone 1, the dominant pathway appears to be 
reformation of the -lactone ring to give the highly activated species [52]. This follows the precedent 
of lactacystin, which similarly gives omuralide in cells [26,27,98].  
5.2. P1 Analogs 
Natural products chemistry and semi-synthesis provided an opportunity to evaluate the role of   
C-5OH. Salinosporamide J (13; C-5H2) is a 20-fold less potent inhibitor of CT-L activity (IC50 = 52 nM) 
than the parent 1, but significantly more active than ketosalinosporamide (35) and C-5-epi-
salinosporamide (36) (IC50 = 8.2 µM and >20 µM, respectively). Thus, reduction of the C-5 hydroxyl 
group to a methylene group is preferred to epimerization or oxidation [34,52]. The crystal structure of 
1  in complex with the yeast 20S proteasome revealed hydrogen-bonding interactions between the 
ligand C-5OH and the proteasome Thr21NH, and further suggested that 35 and 36 may introduce steric 
interactions that are not well tolerated [35]. In the case of 13, the hydrogen bonding potential is lost, 
but problematic steric interactions would not be expected, in agreement with the trends in the assay 
data [IC50 1 < 13 (C-5H2), 35 (keto-C-5) < 35 (epi-C-5OH)] [34,35,52]. 
Cyclohexene ring modification or replacement has been achieved by mutasynthesis [64,65], semi-
synthesis [34] and total synthesis [71,72]. The P1 analogs generated to date largely represent 
hydrophobic hydrocarbons, for which the potency rank order is cycloalkenyl > cycloalkyl > branched 
aliphatic > linear aliphatic > aromatic, with respect to inhibition of CT-L activity. The reduced potency 
of the phenyl analog is in agreement with SAR studies of omuralide [29]. Epoxidation of the 
cyclohexene ring is only well tolerated on one face (37: IC50 = 6.3 nM versus 38: IC50 = 91 nM) [34]. 
Ring contraction from a 6- to a 5-membered ring gave promising results; the cyclopentenyl analog is 
~equipotent with 1 with respect to inhibition of CT-L activity and more cytotoxic against human colon 
carcinoma HCT-116 cells [65]. Given the role of P1 in recognizing the S1 specificity pocket of the 
proteasome, which largely imparts the CT-L, T-L and C-L sites with their substrate cleavage 
preferences, the authors stress the importance of evaluating P1 analogs against all three proteolytic 
sites, which may reveal unique inhibition profiles across subunits.  
5.3. P2 Analogs 
Fermentation extracts of S. tropica contained low levels of compounds 10, 16, and 11, the C-2 
epimers of 1, 5, and 8 [34,52]. These 2(S) diasteromers were >50-fold less potent than their 2(R) Mar. Drugs 2010, 8                                    
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congeners with respect to inhibition of CT-L activity, indicating that the 2(R) stereochemistry of the 
major secondary metabolites is well optimized. In the case of 1, this stereoconfiguration is particularly 
important: the syn relationship of the chloroethyl and C-3OH substituents of the -lactam ring supports 
intramolecular nucleophilic displacement of chloride to give a cis-fused bicyclic lactam upon binding 
to the proteasome (Figure 2), which results in irreversible proteasome inhibition in vitro [35,61].  
P2 analogs were highly instrumental in establishing the mechanistic role of the chloride leaving 
group. Crystallographic studies and proteasome inhibition/recovery experiments using purified 20S 
proteasomes confirmed that displacement of chloride (or alternative leaving groups) at the proteasome 
active site results in irreversible inhibition of proteasome activity [35,61,67]. The irreversible 
inhibitors, which bear a leaving group at the C-13 position of P2 [e.g., Cl (1), Br (15), I (42), and 
various sulfonate esters (46, 47, 48)] are generally more potent proteasome inhibitors when compared 
to their slowly reversible congeners, which do not bear a leaving group at this position [61]. 
Interestingly, fluorosalinosporamide (17) behaves intermediately, which is attributed to the poor 
leaving group potential of fluoride [61]. Slow fluoride elimination in the proteasome active site was 
nicely captured in freeze-frame (short and long soak) crystal structures of 17 in complex with yeast 
20S proteasomes [67]. These findings are in good agreement with its behavior as a partially reversible 
proteasome inhibitor [61] and its intermediate behavior between 1 and 5 [61,63]. However, P2 analogs 
that do not bear a leaving group are still very potent inhibitors of purified 20S proteasomes, with IC50 
values in the low nM range (Table 2). Thus, while the kinetic distinction between slowly reversible 
and irreversible inhibition of purified proteasomes is evident, the greatest impact of irreversible 
binding is on cellular events downstream of proteasome inhibition, whereby sustained proteasome 
inhibition leads to potent cytotoxicity in tumor cells. Indeed, P2 analogs bearing a leaving group 
exhibit much more potent cytotoxicity in hematological and solid tumor cell lines [34,51,59].   
A comprehensive discussion of this and other lessons learned from β-lactone proteasome inhibitors is 
currently in review (M. Groll and B. Potts, 2010).  
6. Total Synthesis of 1 
In this section, the total synthesis of 1 is reviewed. At the time of writing, 5 enantioselective total 
syntheses [39–43], 2 racemic syntheses [44,45], and 5 formal syntheses [46–50] have been published, 
reflecting a wide variety of strategies that often converge to common advanced intermediates. The 
strategies are captured in Schemes 4–15, in which the atom numbering for all intermediates (including 
well known starting materials or their derivatives) correlates with the atom numbers of the final 
synthetic target 1 (Figure 1). The reader is directed to the source articles for supporting references. 
6.1. Enantioselective Synthesis of (-)-1 
6.1.1. Corey Enantioselective Synthesis 
The first total synthesis of 1 was reported by Corey and coworkers [39], marking a key milestone 
and setting the standard for all who followed. Key features of this innovative route included: (i) an 
intramolecular Baylis-Hillman aldol reaction to construct the -lactam with the desired stereochemistry Mar. Drugs 2010, 8                                    
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at the C-3 tertiary alcohol; and (ii) simultaneous construction of the C-5/C-6 stereocenters by allylation 
of a late-stage intermediate aldehyde with 2-cyclohexenyl zinc chloride. 
The overall synthesis is captured in Scheme 4. (S)-threonine methyl ester served as a natural choice 
for the starting material, comprising the C-15/C-4/C-3/C-14 contiguous carbons of 1. N-acylation with 
4-methoxybenzoyl chloride and subsequent p-TsOH catalyzed cyclization gave the corresponding 
oxazoline 1-2. Stereoselective alkylation with ClCH2OBn afforded 1-3 with the desired chirality at the 
quaternary C-4 stereocenter while effectively introducing C-5. Reductive oxazoline ring opening with 
NaBH3CN-HOAc gave PMB derivative 1-4. After TMS-protection, selective N-acylation with acrylyl 
chloride and acidic workup installed the contiguous 3-carbon unit C-1/C-2/C-12; subsequent   
Dess-Martin periodinane oxidation afforded keto amide ester 1-5 in preparation for -lactam formation 
in the next step. This was initially achieved via a quinuclidine base-catalyzed intramolecular Baylis-
Hillman aldol reaction that occurred over 7 days to give -lactam  1-7 with the desired C-3 
stereochemistry with high selectivity (9:1). Both the efficiency and stereoselectivity of this important 
step were subsequently improved with an alternative cyclization strategy that was reported 
independently (vide infra) [72]. The corresponding silyl ether underwent tri-n-butyltin hydride 
mediated radical cyclization to the cis-fused  -lactam  1-8. The benzyl ether was cleaved and the 
resulting alcohol oxidized to obtain key intermediate aldehyde 1-9, which was reacted with   
2-cyclohexenyl zinc chloride to complete the construction of the P1 cyclohexenyl carbinol residue. 
Notably, this diastereoselective allylation introduced the contiguous C-5/C-6 stereocenters 
simultaneously and in high stereoselectivity (20:1). Testament to the remarkable utility of this step is 
best offered by the synthetic routes that subsequently adopted it (vide infra). Tamao-Fleming oxidation 
of 1-10 followed by deprotection of the lactam nitrogen gave triol 1-11. Finally, the methyl ester was 
hydrolyzed to set the stage for clean and efficient -lactone formation and chlorination in one pot to 
give (-)-1 for the first time by total synthesis.  
Scheme 4. Corey and coworkers’ synthesis of (-)-1 from L-threonine methyl ester [39].  
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This “simple stereocontrolled synthesis” of 1 by Corey and coworkers [39] was subsequently 
improved in overall efficiency by replacing the Baylis-Hillman reaction (7 days) with a 
diastereoselective cyclization sequence; treatment of 1-5 with Kulinkovich reagent followed by 
iodination and HI elimination was completed over 5 hours (overall sequence) with remarkable 
selectivity (dr > 99:1). The resulting, highly functionalized -lactam 1-7 is a versatile intermediate, 
serving as a common precursor to 1 and hybrid analogs antiprotealide (14), -methyl omuralide, and 
other potential analogs [72]. This intermediate was later targeted in the formal synthesis of 1 by 
Langlois and coworkers (vide infra) [46]. Moreover, a precursor related to 1-5 but comprising the 
isopropyl carbinol P1 moiety was also advanced to 14 [71], further demonstrating the utility of   
this transformation. 
6.1.2. Danishefsky Enantioselective Synthesis 
The enantioselective synthesis of (-)-1 from a bicyclic derivative of L-glutamic acid was reported 
by Endo and Danishefsky in 2005 [40]. This novel synthesis features a cationic hemiacetal-mediated 
phenylselenenylation of an exocyclic methylene to stereoselectively install the quaternary center at  
C-3; this step, together with subsequent radical deselenylation to provide the C-3 methyl substituent, 
were later adopted by Hatakeyama and coworkers’ in their formal synthesis of 1 [42]. 
Scheme 5. Danishefsky and Endo synthesis of (-)-1 from a pyroglutamate derivative of  
L-glutamic acid [40]. 
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The total synthesis, captured in Scheme 5, exploited the strong facial bias of pyroglutamate 
derivative 2-1 to attack at C-3 from its -face, with subsequent alkylation at C-2 from its -face. The 
vinyl group of the C-3 substituent of intermediate 2-2 was advanced to a carbonate ester acylating 
agent for subsequent intramolecular and stereoselective delivery to C-4. This required that the lactam Mar. Drugs 2010, 8                                    
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functionality be masked in the form of the imidate ester 2-4 to enable exclusive anion formation at  
C-4. The resulting lactone 2-5 carried an advanced stereochemical imprint for further evolution to 1. 
Nucleophilic ring opening of the lactone was achieved regioselectively with a phenylselenium ion, and 
the resulting carboxylic acid was benzylated to give 2-6, thereby differentiating C-5 and C-15. The C-3 
and C-2 substituents were then converted to exocyclic methylene and acetaldehyde moieties, 
respectively (2-7). This set the stage for the hemiacetal-mediated phenylselenenylation of the 
exocyclic methylene, which gave 2-8, thereby establishing the C-3 quaternary center with complete 
stereocontrol. Subsequent radical deselenylation of 2-8 provided the C-3 methyl substituent. With the 
C-2/C-3/C-4 contiguous stereocenters in place, the benzyl ester was converted to the corresponding  
C-5 aldehyde 2-9. Introduction of the cyclohexenyl group was achieved by adopting the elegant 
method established by Corey and coworkers (vide supra) [39]; indeed, allylation using cyclohexenyl 
zinc chloride occurred with the desired stereochemical outcome at C-5 and C-6 to give 2-10. The 
authors noted that allylation of the corresponding imidate aldehyde substrate (derived from 2-4) gave 
poor diastereoselectivity with the same reagent, highlighting the importance of the PMB protecting 
group for diastereoselection [40]. Finally, the corresponding triol 2-11 was unveiled for -lactone 
formation and replacement of the primary alcohol with chloride, ala Corey and coworkers [39].  
6.1.3. Nereus (Ling) Enantioselective Synthesis 
In our own laboratory, a novel enantioselective strategy was envisioned by Taotao Ling that involved 
an intramolecular aldol cyclization to generate key intermediate 3-4 using the Self-Regeneration of 
Stereocenters (SRS) principle developed by Seebach et al.
 [99], as captured in Scheme 6 [41]. The advantage 
of this approach was the efficient, scalable, and simultaneous generation of three contiguous stereocenters 
C-2/C-3/C-4, in contrast with earlier syntheses that employed their stepwise introduction [39,40]. 
Scheme 6. Nereus synthesis of (-)-1 from D-serine [41]. 
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Enantiomerically pure oxazolidine-γ-lactam 3-4 was prepared from ß-keto amide 3-3, where the  
C-4 chirality (derived from D-serine) was maintained during the intramolecular aldol cyclization 
following a strategy previously described by Andrews et al. [100] and the C-2 and C-3 stereocenters 
were simultaneously constructed in a substrate-directed fashion. The resulting, highly functionalized 
intermediate 3-4 served as a key precursor for the enantioselective total synthesis of (-)-1. Thus, the  
D-serine derived oxazolidine served as both a chiral directing group during the intramolecular aldol 
cyclization and as a protecting group during subsequent steps of the synthesis, and would ultimately be 
unveiled to allow oxidation of C-15 in anticipation of ß-lactone formation in the last stages of the 
synthesis. Compound 3-4 was advanced to aldehyde 3-6 in preparation for allylation. Cyclohexene 
ring installation using Corey’s method (with cyclohexenyl zinc chloride) [39] indeed gave an anti 
addition product, but with both undesired C-5 and C-6 stereocenters. This clearly distinguished our 
oxazolidine protected substrate 3-6 from the PMB-protected -lactam used in other routes [39,40,44]. 
We therefore turned to Brown’s allylboration chemistry (i.e., coupling of 3-6 with B-2-cyclohexen-1-
yl-9-BBN [101]), which was expected to give a syn addition product. Fortunately, the product 3-7 had 
the desired stereochemistry at C-6; thus, the required stereochemistry at C-5 would need to be 
generated later, which was known to be feasible based on our prior development of selective semi-
synthetic transformations on the natural product [60] (see 4. Products of Semi-Synthesis). With the 
overall carbon skeleton in place, the oxazolidine-protected alcohol (C-15) was revealed (3-9)  and 
oxidized in preparation for -lactone formation, followed by halogenation of the C-2 sidechain to give 
3-11 (equivalent to compound 36), the C-5 epimer of 1. The final C-5 stereocenter was established by 
Dess-Martin periodinane oxidation to the corresponding ketone 3-12 (equivalent to compound 35), 
which was stereoselectively reduced by a ketoreductase enzyme [41,60] to afford (-)-1. 
In summary, the key features of the enantioselective route developed in our laboratory included 
intramolecular aldol cyclization to simultaneously generate the three contiguous stereocenters of 
intermediate 3-4, of which 100g of material was produced via this scaleable process; cyclohexene ring 
addition using B-2-cyclohexen-1-yl-9-BBN; and inversion of the C-5 stereocenter by oxidation 
followed by enantioselective enzymatic reduction.  
6.1.4. Hatakeyama Enantioselective Synthesis 
Hatakeyama and coworkers’ total synthesis of (-)-1 (Scheme 7) [42] represents a successful 
application of the construction of highly functionalized pyrrolidinones using an indium-catalyzed Conia-
ene reaction. Conia-ene reactions [102] generally require harsh conditions, under which racemization and 
isomerization of the exocyclic olefin from the ,- to the ,-position are of considerable concern, while 
metal catalyzed reactions may be carried out under milder conditions. If the target pyrrolidinone 4-5 
could be obtained by this strategy, advancement to (-)-1 was envisioned as follows. The C-3 quaternary 
center would be constructed stereoselectively by intramolecular delivery of oxygen from the C-2 
substituent to the exo olefin, as established by Endo and Danishefsky [40], while the C-4 center could be 
created by selective reduction of one of the geminal esters of the resulting bicyclic intermediate. This 
would set the stage for cyclohexenyl zinc chloride addition, per Corey and coworkers [39].  
The synthesis was executed as outlined above. Specifically, to prepare amide 4-4, the substrate for 
the key In(OTf)3-catalyzed cyclization, chiral propargyl alcohol 4-1 was converted to the mesylate, Mar. Drugs 2010, 8                                    
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which was then reacted with (t-butyldimethylsilyloxy) acetaldehyde via the allenylzinc species to give 
4-2 as a 9:1 epimeric mixture. Removal of the PMB group, selective acetylation, and desilylation 
afforded 4-3, which was treated with CrO3 and HIO4 in aqueous acetone to obtain the corresponding 
carboxylic acid. Subsequent condensation with dimethyl-2-(4-methoxybenzylamino)malonate via the 
acid chloride afforded the key precursor 4-4, anticipating Conia-ene cyclization. Interestingly, during 
purification on silica gel, amide 4-4 partially underwent cyclization to give an inseparable mixture of 
4-4 and 4-5 (72:28) [Further subjecting this mixture to silica gel chromatography conditions gave 4-5 
quantitatively and in 90% ee, suggesting a silica gel promoted Conia-ene reaction (rather than 
cyclization through the corresponding achiral allenylamide) [42,103]]. Treatment of the mixture of 4-4 
and 4-5 with a catalytic amount of In(OTf)3 in toluene at reflux (the original conditions developed for 
the Conia-ene cyclization!) indeed resulted in complete conversion of 4-4 into 4-5. Importantly, no 
significant loss of enantiomeric purity was observed. Having demonstrated this key transformation, the 
acetoxy group of 4-5 (a base labile intermediate) was hydrolyzed under mild lipase-catalyzed reaction 
conditions to give the corresponding alcohol, which was then oxidized to aldehyde 4-6. This set the 
stage for the assembly of the C-3 quarternary center, which was achieved according to the precedent 
established by Endo and Danishefsky [40] to obtain 4-7 (vide supra). Radical deselenenylation of 4-7 
was followed by selective NaBH4 reduction, which nicely discriminated between the geminal esters, 
after which Dess-Martin periodinane oxidation afforded aldehyde 4-8. Reaction of 4-8 with cyclohex-
2-enylzinc chloride according to Corey and coworkers [39] yielded 4-9 as a single stereoisomer. 
Removal of the PMB group followed by reductive ring opening of the cyclic acetal afforded known 
triol 4-10 (i.e., identical to 1-11, Scheme 4). Finally, dealkylative cleavage of the methyl ester was 
promoted by (Me2AlTeMe)2, adopted from Mulholland et al. [44] (vide infra), followed by   
β-lactonization and chlorination to obtain (-)-1.  
Scheme 7. Hatakeyama and coworkers’ synthesis of (-)-1 based on an indium-catalyzed 
Conia-ene reaction [42]. 
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6.1.5. Omura Enantioselective Synthesis 
It is most fitting that Omura and coworkers, who first discovered lactacystin (2) [23,24], have 
developed a total synthesis of (-)-1  [43]. Their novel strategy (Scheme 8) presents with the early 
construction of the cyclohexene ring, with introduction of the C-5/C-6 stereocenters via a chelation-
controlled aldol reaction. This represents a distinct approach from the many routes that adopted the 
Corey strategy [39] to install the cyclohexene ring. The Omura synthesis also features an 
intramolecular aldol reaction to construct the lactam C-2/C-3 bond and an intermolecular 
Reformatsky-type reaction followed by 1,4-reduction to generate the P2 substituent. 
Scheme 8. Omura and coworkers’ synthesis of (-)-1 through novel cyclohexene 
construction [43]. 
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The initial phase of the total synthesis of (-)-1 comprised generation of aldehyde 5-4 in preparation 
for cyclohexanone addition, and subsequent cyclohexene formation. Towards this end, optically active 
acetate  5-2 was prepared by Wittig olefination of aldehyde 5-1, followed by hydrolysis to the 
corresponding diol, enzymatic desymmetrization, and TBDPS protection of the remaining primary 
alcohol. Then, the corresponding MEM ether underwent intramolecular cyclic carbamation and   
N-PMB protection to obtain 5-3, which was subjected to osmium-catalyzed dihydroxylation followed Mar. Drugs 2010, 8                                    
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by oxidative cleavage of the corresponding diol to give aldehyde 5-4. This set the stage for the 
addition of cyclohexanone via a chelation-controlled aldol reaction quenched with BzCl that 
effectively installed both of the desired C-5 and C-6 stereogenic centers of intermediate 5-5. The next 
step was the conversion of cyclohexanone to cyclohexene, a challenging problem that was solved by 
stereoselectively generating the anti 1,3-diol and derivatization to the corresponding cyclic sulfate 5-6, 
the elimination of which occurred in high yield to give the desired cyclohexene 5-7. 
The next phase of the synthesis involved construction of the -lactam ring and the quaternary C-3 
stereocenter. Intramolecular transcarbamation of 5-7 with NaH followed by Swern oxidation gave 
aldehyde 5–8, which was advanced to the corresponding ketone to provide the required methyl group 
of  1. The nitrogen was deprotected to give 5-9, enabling construction of the -lactam and C-3 
stereogenic center via N-acylation followed by an intramolecular aldol reaction using LHMDS and 
chloroacetyl chloride in one pot, which generated the desired -lactam 5-10 as a single isomer. 
In the final stages of the synthesis, the C-2 side chain (P2) was installed using a SmI2-mediated 
intermolecular Reformatsky-type reaction of 5-10 with benzyloxy acetaldehyde. The resulting   
β-hydroxy--lactam  5-11 was converted to the α,β-unsaturated lactam by mesylation-elimination, 
followed by alkaline hydrolysis and stereoselective 1,4-reduction with LiEt3BH to obtain 5-12. A 
series of selective protection and deprotection steps afforded 5-13, in preparation for oxidation of the 
primary alcohol to enable β-lactonization and finally, chlorination, to generate the desired β-lactone  
5-14, which was deprotected to afford (-)-1.  
6.2. Racemic Synthesis of (±)-1 
6.2.1. Pattenden Racemic Synthesis 
The concise racemic route developed by Pattenden and coworkers (Scheme 9) was first 
communicated in 2006 [44], and a full account was reported in 2008 [104].  The straightforward   
14-step total synthesis commenced with intramolecular aldol cyclization of protected -keto-amide 6-2 
to generate -lactam (±)-6-3. This approach nicely parallels the strategy pursued in our own   
laboratory [41], albeit without enantioselective control. Nevertheless, the cyclization gave the required 
relative stereochemistry at C-2 and C-3, which was controlled with careful attention to the temperature 
of this deprotection-aldol cyclization reaction. After TMS and PMB protection of the tertiary alcohol 
and lactam nitrogen, respectively, dimethyl ester 6-4 underwent regioselective superhydride reduction 
to give C-5 aldehyde 6-5; specifically, the methoxycarbonyl trans to the sterically hindered C-3OTMS 
group of intermediate 6-4 underwent selective reduction, successfully exploiting the facial bias of the 
substrate. The remainder of the synthesis, including stereoselective allylation with cyclohexenyl zinc 
bromide, was concluded in analogy to the strategy of Corey and coworkers [39] to give (±)-1. Of note, 
dimethylaluminium methyltelluride (60% yield) was used in place of 3M LiOH (<10% yield) to 
hydrolyze the methyl ester of 6-7, prior to lactonization and chlorination.  
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Scheme 9. Pattenden and coworkers’ synthesis of (±)-1 [44,104]. 
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6.2.2. Romo Racemic Synthesis 
The synthesis of (±)-1 by Romo and coworkers [45] was a natural extension of their keen interest in 
constructing carbocycle-fused -lactones (e.g., [105]). Their strategy comprised the coupling of an  
-amino acid with a heteroketene dimer, the product of which underwent nucleophile promoted bis-
cyclization to simultaneously construct the highly functionalized -lactone--lactam core (±)-7-6a. 
The cyclohexenyl group was successfully introduced at the penultimate stage of the synthesis, 
demonstrating the stability of both the -lactone and chloroethyl functionalities to the conditions of 
this key reaction, thereby suggesting strong potential for the generation of a variety of P1 analogs from 
late stage aldehyde intermediate 7-7. 
The details of this concise synthetic route are captured in Scheme 10. N-PMB serine allyl ester 7-2 
was coupled with heteroketene dimer 7-3; this key interemediate was reportedly readily generated in 
gram quantities. The resulting -keto amide underwent Pd-mediated ester deprotection to give 7-4 in 
anticipation of the key bis-cyclization reaction, which was executed with modified Mukaiyama reagent 
7-5 to activate the carboxylic acid in the form of a pyridone ester (not shown). The desired -lactone-
-lactam 7-6a was obtained in 2-3:1 dr. Deprotection of the benzyl ether followed by modified Moffatt 
oxidation to the corresponding aldehyde 7-7 set the stage for treatment with cyclohexenyl zinc 
chloride to complete the P1 moiety and simultaneously establish the C-5/C-6 stereocenters, according 
to the precedent of Corey and coworkers [39]. Final unveiling of the lactam nitrogen gave (±)-1. This 
approach was also extended to the total synthesis of the related (±)-cinnabaramide A [45]. 
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Scheme 10. Romo and coworkers’ racemic synthesis of (±)-1 [45]. 
 
1. p-anisaldehyde,
    NaBH4
2. p-TSA, allyl alcohol
       74% (2 steps)
BnO
CO2H
ZnCl
33% (2 steps)
NH2
BnO
CO2allyl
NHPMB
O
O
Cl
2-hydroxypyridine, 80%
2. Pd(PPH3)4, 
    morpholine, 75%
OBn
HO2C
N
PMB
O O
Cl
1.
N Br
n-Pr OTf
i-Pr2NEt, PPY
 (25-35%)
N
O
Cl
PMB
O
O
OBn
N
O
Cl
PMB
O
O
OBn
+
(dr 2-3:1)
1. H2, Pd/C
    98%
2. EDCI, 
   Cl2CHCO2H
N
O
Cl
PMB
O
O CHO
N
O
Cl
PMB
O
O
(dr 3.5:1)
OH
(±)-1
CAN
49%
7-1 7-2
(±)-7-3
7-4
7-5
(±)-7-6b (±)-7-6a (±)-7-7 (±)-7-8
2
3 4 5
5
4
2
3
1
6
5
5
 
6.3. Formal Synthesis of 1 
6.3.1. Langlois Formal Synthesis  
Langlois and co-workers [46] developed a synthesis of (2R,3S)-α-methylene--lactam 8-10, a key 
intermediate in Corey and coworkers’ synthesis of 1 [39]. This formal synthesis represents an 
extension of their earlier efforts in which the corresponding N-Boc racemic scaffold was   
generated [106], providing a foundation for the development of an asymmetric route to N-PMB 
intermediate 8-10 from (S)-methyl 2-hydroxymethyl pyroglutamate (8-2) [46]. 
The formal synthesis of 1 is outlined in Scheme 11. Chiral intermediate (S)-8-2 had been previously 
generated by Langlois and Nguyen from bicyclic nitrile 8-1 in their synthesis of deoxydysibetaine 
[107] and was prepared accordingly. Then, selective O-benzylation of (S)-8-2 was achieved with   
2-benzyloxy-1-methylpyridinium triflate as a mild and nearly neutral benzylating agent in the presence 
of MgO, giving (S)-8-3 in 75% yield. According to their prior work [106], the subsequent steps in the 
synthesis would not induce racemization, thus, the remainder of the formal synthesis was demonstrated 
using racemic 8-3. Towards this end, the N-PMB derivative of 8-3 was generated (not shown), 
however, subsequent introduction of the conjugate double bond was low yielding compared to that 
achieved previously with the corresponding N-Boc derivative. Consequently, introduction of the PMB 
group was reserved for a later stage of the synthesis, and 8-3 was instead Boc-protected for 
advancement to 8-6 by means established previously [106]. Specifically, introduction of the conjugate 
double bond was achieved via phenylselenylation using LDA as a base followed by selenoxide 
elimination; the resulting intermediate 8-4 could be used to prepare -methyl unsaturated lactam 8-6 
via two possible pathways: (i) treatment with diazomethane to give pyrazolines 8-5a and 8-5b, 
followed by thermolysis (overall 35%); or (ii) stereoselective addition of the C-3 methyl group using 
methylcuprate to give 8-5c, with subsequent introduction of the double bond via phenylselenylation 
and selenoxide elimination (overall 63%). Thereafter, the Boc group of pyrrolinone 8-6 was removed 
and the nitrogen was PMB-protected to give 8-7. This set the stage for the selective 1,3-dipolar Mar. Drugs 2010, 8                                    
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cycloaddition of N-methylnitrone to simultaneously introduce the C-3 oxygen and the precursor to the 
exo-methylene group. Specifically, formation of cycloadducts 8-8a and 8-8b was achieved by heating 
8-7 with N-methylnitrone in toluene, which gave 8-8a as the major product. The isoxazolidine ring 
was hydrogenolyzed in the presence of Pd(OH)2, affording 8-9. Finally, the target α-methylene--
lactam 8-10 was obtained by forming the trimethylammonium salt with iodomethane in methanol, 
which was further treated with a biphasic mixture of aqueous Na2CO3 and CH2Cl2 (4 days at room 
temperature) to induce elimination to the exo-methylene group in high yield [46]. This completed the 
formal synthesis, as intermediate 8-10 was previously advanced to 1 by Corey and coworkers [39].  
Scheme 11. Langlois and coworkers’ stereoselective formal synthesis of 1. Synthesis of  
8-2 from 8-1 was performed according to [107]. 8-10 was synthesized from 8-2  as 
described in [47,106]. 
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6.3.2. Lam Formal Synthesis 
Lam and co-workers achieved a formal synthesis of 1 using a sequential nickel-catalyzed reductive 
aldol cyclization-lactonization reaction as a key step [47]. ,-unsaturated amide 9-3 was targeted as a 
highly functionalized substrate for this reaction, which would give rise to an advanced -lactam 
comprising the precursor to the P2 substituent. A related cyclization of a less densely functionalized 
substrate had been achieved previously [108]. Thus, application to 9-3, which was more sterically Mar. Drugs 2010, 8                                    
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congested and comprised several Lewis basic groups that could potentially bind the catalyst and 
reductant and divert the course of the intended reaction, along with only a single stereocenter to 
control the absolute configurations of the two new centers generated upon cyclization, presented 
significant challenges that would rigorously test this methodology.  
The formal synthesis is captured in Scheme 12 and commenced with Swern oxidation of known 
amino alcohol 9-1 [39] to give aminoketone 9-2, which was then suitably acylated to afford the target 
α,β-unsaturated amide 9-3 in high yield. This set the stage for the key reductive aldol cyclization 
reaction, which was attempted using a variety of conditions. Commercially available nickel-phosphine 
complexes (Ph3P)2NiBr2 and (Me3P)2NiCl2 were identified as effective precatalysts when used in 
conjunction with Et2Zn reductant, and although the target 9-4c was not formed, a fused -lactam--
lactone 9-5a (presumably generated via 9-4a) with the desired stereochemistry was isolated in 35% 
and 42% yields, respectively. This provided the unexpected benefit of protecting the C-3 tertiary 
alcohol during subsequent steps. To complete the synthesis, 9-5a underwent Pd-catalyzed 
debenzylation to afford alcohol 9-6, which was oxidized to the corresponding aldehyde 9-7  via  
Dess-Martin periodinane oxidation [47]. Due to its relative instability, the aldehyde was immediately 
reacted with 2-cyclohexenylzinc chloride as described by Corey and coworkers
  [39] to give 
homoallylic alcohol 9-8. The formal synthesis was completed by reductive ring opening of the 9-8 
lactone using NaBH4 to give triol 9-9, for which the conversion to 1 had been previously described by 
the Corey [39] and Pattenden groups [44]. 
Scheme 12. Lam and coworkers’ formal synthesis of 1 using a nickel-catalyzed reductive 
aldol cyclization-lactonization as a key step [47]. 
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6.3.3. Bode Formal Synthesis  
Struble and Bode have explored N-heterocyclic carbene (NHC) catalyzed intramolecular 
lactonization to prepare densely functionalized bicyclic -lactam--lactone adducts from enals. This 
methodology was applied to their formal synthesis of 1 (Scheme 13) based on its potential for a 
concise and high yielding entry to the core bicyclic -lactam--lactone scaffold 10-6a [48]. 
The synthesis of 10-1 from L-threonine was established previously by Corey and coworkers in their 
synthesis of 1 [39]. To generate target aldehyde 10-4, compound 10-1 was derivatized to 10-2 using a 
three step sequence comprising N-acylation with sorbyl chloride, silyl ether cleavage under aqueous 
acidic conditions and Dess-Martin oxidation. Subsequent regioselective sharpless dihydroxylation at 
the ,δ-position of 10-2 afforded diol 10-3 as a single diastereomer. The diol was cleaved with sodium 
periodate to yield terminal aldehyde 10-4, setting the stage for the key NHC-catalyzed asymmetric 
intramolecular cyclization. Using N-mesityl aminoindanol derived chiral triazolium catalyst 10-5, 
bicyclic -lactam--lactone diastereomers 10-6a (desired) and 10-6b (undesired) were obtained in high 
yield (88%) in a diastereomeric ratio of 1:1.1. -Lactam--lactone 10-6a is identical to 9-5a (Scheme 12) 
targeted by Lam and coworkers [47], thereby representing a formal synthesis of 1. 
Scheme 13. Bode and Struble formal synthesis of 1 via NHC-catalyzed intramolecular 
lactonization [48]. 
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6.3.4. Tepe Formal Synthesis 
Mosey and Tepe demonstrated the utility of an ene-type alkylation reaction to construct Corey’s 
intermediate ketone 11-7 [39] using an oxazol-5-(4H)-one (“oxazolone”) and an enol ether in their 
formal synthesis of (±)-1 (Scheme 14) [49]. The broader utility of oxazolones in the construction of 
other natural products has also been reviewed by Tepe and coworkers [109]. 
Ene-type alkylation of racemic oxazolone 11-1 with t-butyl enol ether followed by sodium 
borohydride reduction gave 11-2 in 88% yield as a 3:1 mixture of diastereomers. The major 
diastereomer was advanced to the target, however, the authors observe that both diastereomers could 
be used to generate (±)-1, since the second stereocenter (C-3) is ultimately destroyed during oxidation Mar. Drugs 2010, 8                                    
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of 11-6 or 11-9 to the corresponding ketone 11-7. The amide functionality of 11-2 was selectively 
reduced by dehydrative cyclization under basic conditions with MsCl, followed by reduction of the 
resulting oxazoline 11-3 with NaCNBH3 in acetic acid to afford N-PMB-protected amino alcohol 11-4. 
The primary alcohol was subsequently protected to give benzyl ether 11-5. Acylation with acrylyl 
chloride was smoothly executed according to Corey and coworkers [39] to obtain amide 11-8. 
However, deprotection of the t-butyl group with TFA or phosphoric acid to obtain alcohol 11-9 as a 
single diastereomer was low yielding (25% or 27%), suggesting that earlier stage removal may be 
preferable. Indeed, conversion of 11-5 to 11-6 was more rapid (6h) and high yielding (98%). Target 
ketone 11-7 could be obtained from either 11-6 or 11-9 according to Corey’s synthesis [39], thereby 
completing the formal synthesis of (±)-1. 
Scheme 14. Tepe and Mosey formal synthesis of (±)-1 [49]. 
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6.3.5. Chida Formal Synthesis 
Chida and coworkers previously demonstrated that Overman rearrangement on sugar-derived 
scaffolds followed by further exploitation of residual carbohydrate functional groups is a successful 
methodology for the synthesis of natural products comprising -substituted -amino acids, including 
lactacystin [110]. Accordingly, Momose et al. reported the formal synthesis of (-)-1 from D-glucose, 
featuring Overman rearrangement of allylic trichloroacetimidate 12-14 to construct the quaternary   
C-4 stereocenter bearing nitrogen (12-15). During this step, the chiral information was relayed from 
the C-3 stereocenter, which had been previously generated with complete stereoselectivity under 
substrate control by reaction of D-glucose-derived cyclic ketone 12-8 with Me3Al (Scheme 15) [50]. Mar. Drugs 2010, 8                                    
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The synthesis commenced with diacetone-D-glucose, which was advanced to primary alcohol 12-1 
in 4 steps according to Fleet et al. [111], followed by protection with BnBr to obtain 12-2. The 
exocyclic acetonide was selectively cleaved to the corresponding diol 12-3, which was suitably 
protected (12-5). Hydrolysis of the remaining acetonide and cleavage of the resulting glycol afforded 
pyranose derivative 12-6. The corresponding PMB β-glycoside was generated and the O-formyl group 
removed to give pyranoside 12-7, which was oxidized with DMSO-Ac2O to obtain ketone 12-8 in 
preparation for generation of the C-3 tertiary alcohol. This important step was achieved 
stereoselectively upon reaction with Me3Al in toluene, which afforded 12-9 as the sole product in high 
yield. The high stereoselectivity occurred under substrate control, specifically, in the presence of the 
bulky alkyl side chain and the OTs group flanking the ketone carbonyl. Tosyl group deprotection was 
achieved using Mg in MeOH to give 12-10, followed by oxidation of the secondary alcohol to a ketone 
(12-11) in anticipation of generating the key allylic trichloroacetimidate 12-14. Towards, this end,  
12-11 underwent Horner-Wadsworth-Emmons reaction with subsequent TMS protection of the tertiary 
alcohol to afford E-alkene 12-12 as a single isomer. After reduction of the ester with DIBAL-H, the 
primary alcohol 12-13 was converted into trichloroacetimidate 12-14 via CCl3CN and DBU. This set 
the stage for the centerpiece of the synthesis, the Overman rearrangement, which was executed in  
t-butyl benzene at 150 °C in the presence of Na2CO3 in a sealed tube for 2 days, and gave rise to the 
desired isomer 12-15 and its C-4 epimer (not shown) in 69% and 16% isolated yields, respectively. 
The observed stereoselectivity was rationalized by considering both steric and electronic factors of two 
possible chair-like transition state intermediates, with the desired isomer obtained from the transition 
model which did not give rise to repulsive interactions between the nitrogen and the neighboring  
TMS group.  
Having successfully demonstrated the key transformation, 12-15 was advanced to Corey’s 
intermediate 12-24  [39]. First, the acetal needed to be transformed to a hemiaminal that could be 
oxidized to the desired -lactam. Towards this end, the trichloroacetyl group in 12-15 was replaced 
with Cbz to give 12-16. Then, hemiaminal formation was achieved in two ways: i) removal of the 
PMB group with DDQ and subsequent treatment with TBAF revealed hemiacetal 12-17, which was 
spontaneously converted into 5-membered hemiaminal 12-18 (67%); and ii) treatment with aqueous 
TFA in methylene chloride, which gave 12-18 in one step (96%). Jones oxidation generated -lactam 
12-19; interestingly, the primary alcohol was oxidized only to the aldehyde, which was attributed to 
severe steric hindrance circumventing the formation of the bulky chromate ester. Further oxidation 
was required to create the precursor for downstream -lactone formation and was achieved using 
NaClO2, with subsequent esterification to methyl ester 12-20 in 44% overall yield from 12-16. 
Protection of the tertiary alcohol and oxidative cleavage of the vinyl group with OsO4 and NaIO4 gave 
aldehyde 12-22 in preparation for reaction with cyclohex-2-enylzinc chloride as described by Corey’s 
group [39]; this gave 12-23 as the sole product in 90% yield. Unveiling of the corresponding triol was 
executed with BCl3 to afford Corey’s intermediate 12-24, thereby completing the formal   
synthesis of 1.  
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Scheme 15. Chida and coworkers’ formal synthesis of (-)-1 from D-glucose [50]. 
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7. Closing Remarks 
The novel structure and biological activity of 1 have inspired scientists from a variety of disciplines 
to target the salinosporamides for optimal production and analoging using traditional fermentation, 
industrial microbiology, classic natural products chemistry and semi-synthesis, total synthesis, and 
bioengineering. The resulting compounds have provided important insights into SAR, with the 
majority of structural modifications centered around P1 and P2. The P2 analogs have been excellent 
subjects for crystallographic studies in complex with the 20S proteasome, which together with SAR, 
firmly established the role of the leaving group in the mechanism of irreversible binding and prolonged 
duration proteasome inhibition in vitro and in vivo. Mutasynthesis offers a powerful technique to 
generate new P1 analogs, and has been complemented by total and semi-synthetic approaches. Clearly, 
the potential to generate proteasome subunit specific inhibitors exists, but apparently remains 
unfulfilled at the time of writing. With respect to the total synthesis of the parent natural product 1, its 
dense functionality has attracted the attention of some of the most prestigious laboratories in the world. Mar. Drugs 2010, 8                                    
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The growing number of total and formal syntheses promises the inevitable convergence to streamlined 
processes. However, in a powerful demonstration of industrial marine microbiology, S. tropica 
remains the formidable champion of robust production of 1, fueling extensive preclinical studies and 
ongoing clinical trials, and demonstrating that the "supply issue" often associated with natural products 
can be overcome. Indeed, it is the parent natural product that is currently under clinical evaluation in 
patients with hematological and solid tumor malignancies. The remarkable progress demonstrated over 
a period of 7 years since the first publication of 1 by Fenical and coworkers anticipates new frontiers 
of achievement in the future of this important class of proteasome inhibitor. Beyond the current 
landscape of cancer therapeutics, the application of β-lactone proteasome inhibitors in the fight against 
microbial pathogens [7,8] is on the horizon.  
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